{"text": "Primary analyses for both trials are expected in late 2014 to early 2015 .Adjuvant aromatase inhibitor trials .It is important to note that AIs are ineffective in pre - menopausal women with functioning ovaries [ 33 ] .", "label": "", "metadata": {}, "score": "36.580566"}
{"text": "[ 44 , 55 , 60 , 68 - 70 ] .Table 3 summarizes the incidence of treatment - related SAEs in the main adjuvant trials comparing AIs with tamoxifen .", "label": "", "metadata": {}, "score": "36.604332"}
{"text": "All the 6 randomised control trials [ 15 - 20 ] addressed third - generation bisphosphonates and aromatase inhibitors treatment effect in breast cancer treatment ( Figure 1 ) .", "label": "", "metadata": {}, "score": "37.802425"}
{"text": "Eligible patients will be randomized into the YSJG group or the placebo group by obtaining medicines associated with the given drug codes in accordance with the order of visits .", "label": "", "metadata": {}, "score": "40.568584"}
{"text": "The ATAC trial was the first trial to present data comparing adjuvant tamoxifen with an AI , and its results heralded a major change in the endocrine therapy of post - menopausal women .", "label": "", "metadata": {}, "score": "41.873894"}
{"text": "10.1200/JCO.20.3.751 PubMed View Article .Baum M , Budzar AU , Cuzick J , Forbes J , Houghton JH , Klijn JG , Sahmoud T : Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer : first results of the ATAC randomised trial .", "label": "", "metadata": {}, "score": "42.10871"}
{"text": "Other extended adjuvant therapy trials with aromatase inhibitors .Other trials have been conducted to investigate the role of extended adjuvant AI therapy ( Table 1 ) .", "label": "", "metadata": {}, "score": "42.240227"}
{"text": "Third - generation aromatase inhibitors ( AIs ; that is , anastrozole , letrozole and exemestane ) have become the standard of care for the adjuvant treatment of hormone - responsive breast cancer in postmenopausal women .", "label": "", "metadata": {}, "score": "43.64711"}
{"text": "Up to half of patients on AI therapy experience musculoskeletal symptoms , and up to 20 % will discontinue therapy because of intolerable side effects ; therefore , AIMSS has become an important clinical issue requiring effective management .", "label": "", "metadata": {}, "score": "43.749992"}
{"text": "Geisler J , King N , Anker G , Ornati G , Di Salle E , Lonning PE , Dowsett M : In vivo inhibition of aromatization by exemestane , a novel irreversible aromatase inhibitor , in postmenopausal breast cancer patients .", "label": "", "metadata": {}, "score": "44.645943"}
{"text": "Incidence of treatment - related serious adverse events in the main adjuvant aromatase inhibitor trials [ 71 ] .TE event : 0.4 versus 0.2 ( NR )", "label": "", "metadata": {}, "score": "44.776306"}
{"text": "Dowsett M , Cuzick J , Ingle J et al ( 2010 ) Meta - analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen .", "label": "", "metadata": {}, "score": "45.218773"}
{"text": "These three trials evaluate the effect of upfront and delayed zoledronic acid for the prevention of bone loss in postmenopausal women with early breast cancer .", "label": "", "metadata": {}, "score": "45.286842"}
{"text": "Investigators .JAMA 282:637 - 645 CrossRef PubMed .Howell A , Cuzick J , Baum M et al ( 2005 ) Results of the ATAC ( Arimidex , Tamoxifen , Alone or in Combination ) trial after completion of 5 years ' adjuvant treatment for breast cancer .", "label": "", "metadata": {}, "score": "45.68793"}
{"text": "However , this comparison was made directly through random assignment in both the BIG 1 - 98 and the Tamoxifen Exemestane Adjuvant Multinational ( TEAM ) ( see below ) trials and neither has shown any basis for this hypothesis .", "label": "", "metadata": {}, "score": "45.75814"}
{"text": "10.1200/JCO.2005.05.4882 PubMed View Article .Forbes JF , Cuzick J , Buzdar A , Howell A , Tobias JS , Baum M : Effect of anastrozole and tamoxifen as adjuvant treatment for early - stage breast cancer : 100-month analysis of the ATAC trial .", "label": "", "metadata": {}, "score": "45.89329"}
{"text": "Abstract .Background .Aromatase inhibitors ( AIs ) are widely used as an adjuvant endocrine treatment in postmenopausal women with early - stage breast cancer .", "label": "", "metadata": {}, "score": "46.01626"}
{"text": "513 - 529 , 1995 .View at Google Scholar \u00b7 View at Scopus . A. Buzdar , J. Douma , N. Davidson et al . , \" Phase III , multicenter , double - blind , randomized study of letrozole , an aromatase inhibitor , for advanced breast cancer versus megestrol acetate , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.021088"}
{"text": "Results Forty - four of 97 eligible patients ( 45.4 % ) met criteria for rheumatologic referral .Three patients were ineligible because of elevated baseline HAQ ( 2 ) and failure to initiate AI therapy ( 1 ) .", "label": "", "metadata": {}, "score": "46.15013"}
{"text": "PubMed View Article .Rastelli AL , Taylor ME , Gao F , Armamento - Villareal R , Jamalabadi - Majidi S , Napoli N , Ellis MJ : Vitamin D and aromatase inhibitor - induced musculoskeletal symptoms ( AIMSS ) : a phase II , double - blind , placebo - controlled , randomized trial .", "label": "", "metadata": {}, "score": "46.19239"}
{"text": "Aromatase inhibitor toxicities and comparative toxicities with tamoxifen .AIs are associated with a higher incidence of musculoskeletal adverse events ( MSAEs ) ( for example , myalgias and arthralgias ) , bone fractures , and decreased bone mineral density ( BMD ) [ 44 , 60 - 67 ] .", "label": "", "metadata": {}, "score": "46.19735"}
{"text": "AIs are commonly associated with musculoskeletal symptoms .The primary objective of this study was to describe the musculoskeletal symptoms that developed in the first 100 subjects enrolled who had at least 6 months follow - up .", "label": "", "metadata": {}, "score": "46.79029"}
{"text": "Abstract .Summary .Aromatase inhibitors ( AIs ) are widely used in women with breast cancer , but they are known to increase bone loss and risk of fractures .", "label": "", "metadata": {}, "score": "46.82995"}
{"text": "Introduction .Aromatase inhibitors ( AIs ) are now the standard treatment for hormone receptor - positive breast cancer .However , deleterious effects of AIs on bone health have been reported .", "label": "", "metadata": {}, "score": "46.998917"}
{"text": "S3-S18 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W.-B. Zhou , P.-L. Zhang , X.-A. Liu , T. Yang , and W. He , \" Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment : a meta - analysis , \" Journal of Experimental & Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "47.125813"}
{"text": "There is evidence from neoadjuvant studies suggesting that ER + HER2 + ( human epidermal growth factor receptor ) patients might respond better to AIs than to tamoxifen [ 95 - 97 ] .", "label": "", "metadata": {}, "score": "47.390923"}
{"text": "PubMed View Article .Santen RJ , Worgul TJ , Samojlik E , Interrante A , Boucher AE , Lipton A , Harvey HA , White DS , Smart E , Cox C , Wells SA : A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer .", "label": "", "metadata": {}, "score": "47.442646"}
{"text": "Microdose GnRH agonist flare protocols have been shown to be an effective treatment for poor responders , with randomized trials supporting significantly higher implantation rates compared to GnRH antagonist protocols [ 21 , 22 ] .", "label": "", "metadata": {}, "score": "47.546158"}
{"text": "Aromatase inhibitor Arthralgia Breast cancer Musculoskeletal symptoms Rheumatology .Share .References .Baum M , Budzar AU , Cuzick J et al ( 2002 ) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer : first results of the ATAC randomized trial .", "label": "", "metadata": {}, "score": "47.661827"}
{"text": "In post - menopausal women , aromatase inhibitors ( AIs ) ( letrozole , anastrozole , or exemestane ) are superior to tamoxifen in preventing recurrence but only letrozole has been shown to improve survival .", "label": "", "metadata": {}, "score": "47.738503"}
{"text": "10.1200/JCO.2007.14.8700 .View Article .Demirol A , Gurgan T : Comparison of microdose flare - up and antagonist multiple - dose protocols for poor - responder patients : a randomized study .", "label": "", "metadata": {}, "score": "47.889168"}
{"text": "A neuropsychological cross - sectional study from the TEAM trial evaluated the cognitive functioning during the first year 's treatment [ 90 ] .Thus , the evidence of the effects of adjuvant endocrine therapy on cognitive function is limited and inconclusive , and further studies are required .", "label": "", "metadata": {}, "score": "47.943745"}
{"text": "14 , pp .3357 - 3366 , 2001 .View at Google Scholar \u00b7 View at Scopus .J. M. Nabholtz , A. Buzdar , M. Pollak et al . , \" Anastrozole is superior to tamoxifen as first - line therapy for advanced breast cancer in postmenopausal women : results of a North American multicenter randomized trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "48.00073"}
{"text": "Table 4 .Outcomes in relation to specific adverse events in the Tamoxifen Exemestane Adjuvant Multinational ( TEAM ) trial [ 82 ] .AE , adverse event ; CI , confidence interval ; DFS , disease - free survival ; DM , distant metastases ; MSAE , musculoskeletal adverse event ; OS , overall survival ; VMS , vasomotor symptoms ; VVS , vulvovaginal symptoms .", "label": "", "metadata": {}, "score": "48.175037"}
{"text": "Essentially , the trial has four arms comparing goserelin/ tamoxifen to goserelin/ anastrazole , with or without zoledronic acid , and followed a 2x2 factorial design .", "label": "", "metadata": {}, "score": "48.190475"}
{"text": "Current practice and future implications .At the moment existing evidence for the use of aromatase inhibitors as part of an IVF / ICSI protocol is fragmented and weak .", "label": "", "metadata": {}, "score": "48.478912"}
{"text": "To date , there is still a lack of prospective , randomized , controlled trials to provide powerful evidence supporting the use of various treatment modalities .", "label": "", "metadata": {}, "score": "48.79135"}
{"text": "To date , no effective management of aromatase inhibitor - associated musculoskeletal symptoms ( AIMSS ) has been developed .Methods / design .To determine whether the traditional Chinese medicine Yi Shen Jian Gu granules could effectively manage AIMSS we will conduct a multicenter , randomized , double - blind , placebo - controlled clinical trial .", "label": "", "metadata": {}, "score": "48.793625"}
{"text": "This study has some limitations , the most important of which include that it is retrospective , non - powered , non - randomized and not blinded .", "label": "", "metadata": {}, "score": "49.029358"}
{"text": "In the ATAC trial , impairments in processing speed and verbal memory were reported in women on anastrozole as compared with healthy women [ 86 ] .", "label": "", "metadata": {}, "score": "49.20539"}
{"text": "A web page was developed , which asked physicians five main questions , after collecting data on their profile and country of practice .The questions asked about the choice of physicians hormonal agent in early adjuvant setting for the postmenopausal women without having a significant co - morbid , such as a history of osteoporosis , stroke , ischemic heart disease , and hyperlipidemia .", "label": "", "metadata": {}, "score": "49.240273"}
{"text": "View at Google Scholar . H. Iwata , N. Masuda , S. Ohno et al . , et al . , \" A randomized , double - blind , controlled study of exemestane versus anastrozole for the first - line treatment of postmenopausal Japanese women with hormone - receptor - positive advanced breast cancer , \" Breast Cancer Research and Treatment , vol .", "label": "", "metadata": {}, "score": "49.40653"}
{"text": "Eur J Cancer 42:1044 - 1051 CrossRef PubMed .Mouridsen HT , Robert NJ ( 2005 )The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women .", "label": "", "metadata": {}, "score": "49.4247"}
{"text": "J Clin Oncol 2008 , 26 : 1965 - 1971 .10.1200/JCO.2007.14.0228 PubMed View Article .Cuzick J , Sestak I , Baum M , Buzdar A , Howell A , Dowsett M , Forbes JF : Effect of anastrozole and tamoxifen as adjuvant treatment for early - stage breast cancer : 10-year analysis of the ATAC trial .", "label": "", "metadata": {}, "score": "49.46502"}
{"text": "All three available AIs Anastrozole , Letrozole , and Exemestane have been separately compared with Tamoxifen [ 16 ] .The intergroup Exemestane study studied switching to Exemestane after initial 2 - 3 years of Tamoxifen therapy in more than 4500 patients and showed improved disease free and a modest improvement in overall survival in ER positive women [ 17 ] .", "label": "", "metadata": {}, "score": "49.522694"}
{"text": "The interim analysis has 472 DFS events , which is triple the number in this study .3 ) what are implications for other tumor types .", "label": "", "metadata": {}, "score": "49.72426"}
{"text": "However , recent clinical trials of AIs have shown benefits over tamoxifen .The main advantages are improvement of disease - free survival , decreased rates of contralateral breast cancer and a more favorable toxicity profile , with lower rates of thromboembolic phenomena and endometrial malignancy [ 2 - 8 ] .", "label": "", "metadata": {}, "score": "49.93965"}
{"text": "10.1093/humrep / deh359 .View Article .Ozmen B , Sonmezer M , Atabekoglu CS , Olmus H : Use of aromatase inhibitors in poor - responder patients receiving GnRH antagonist protocols .", "label": "", "metadata": {}, "score": "50.035484"}
{"text": "Cuzick J , Sestak I , Baum M et al ( 2010 )Effect of anastrozole and tamoxifen as adjuvant treatment for early - stage breast cancer : 10-year analysis of the ATAC trial .", "label": "", "metadata": {}, "score": "50.068993"}
{"text": "35 , pp .5132 - 5139 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Fizazi , A. Lipton , X. Mariette et al . , \" Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer , breast cancer , or other neoplasms after intravenous bisphosphonates , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "50.09179"}
{"text": "Gnant M , Mlineritsch B , Stoeger H et al ( 2011 )Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early - stage breast cancer : 62-month follow - up from the ABCSG-12 randomised trial .", "label": "", "metadata": {}, "score": "50.52997"}
{"text": "An informed consent was obtained from all participants clearly denoting the off - label use of the medication prior to treatment .Subsequently IRB approval was obtained to use their data for the purposes of this study .", "label": "", "metadata": {}, "score": "50.650024"}
{"text": "- 4890 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. M. Guisado , A. S. Mu\u00f1oz , M. De La Cabeza Lomas Garrido et al . , \" Initialization of adjuvant hormonal treatment for breast cancer , \" Advances in Therapy , vol .", "label": "", "metadata": {}, "score": "50.890335"}
{"text": "39 , no . 1 , pp .83 - 87 , 2004 .View at Google Scholar \u00b7 View at Scopus . A. Llombart , A. Frassoldati , O. Paija et al . , \" Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer : 12-month analysis of the E - ZO - FAST trial , \" Clinical Breast Cancer , vol .", "label": "", "metadata": {}, "score": "50.925995"}
{"text": "10.1016/j.rbmo.2009.05.007 .View Article .Davar R , Oskouian H , Ahmadi S , Firouzabadi RD : GnRH antagonist / letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization .", "label": "", "metadata": {}, "score": "51.097595"}
{"text": "PubMed View Article .Henry NL , Banerjee M , Wicha M , Van Poznak C , Smerage JB , Schott AF , Griggs JJ , Hayes DF : Pilot study of duloxetine for treatment of aromatase inhibitor - associated musculoskeletal symptoms .", "label": "", "metadata": {}, "score": "51.099113"}
{"text": "10.1210/jc.2006 - 0962 .View Article .Azim AA , Costantini - Ferrando M , Lostritto K , Oktay K : Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization .", "label": "", "metadata": {}, "score": "51.161957"}
{"text": "PubMed View Article .Buzdar A , Howell A , Cuzick J , Wale C , Distler W , Hoctin - Boes G , Houghton J , Locker GY , Nabholtz JM : Comprehensive side - effect profile of anastrozole and tamoxifen as adjuvant treatment for early - stage breast cancer : long - term safety analysis of the ATAC trial .", "label": "", "metadata": {}, "score": "51.18692"}
{"text": "J Clin Oncol 14(1):78 - 84 PubMed .The ATAC Trialists ' Group ( 2003 ) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early - stage breast cancer .", "label": "", "metadata": {}, "score": "51.18949"}
{"text": "A detailed list of the participants is given in Table 1 .In response to question \" What is your first choice of hormonal agent in early adjuvant setting for receptor positive postmenopausal breast cancer patients , without significant comorbid like osteoporosis , DVT , heart disease ? \" 36.3 % chose Anastrozole as their choice of therapy , 35.2 % favored tamoxifen , and 22 % preferred Letrozole as their first choice .", "label": "", "metadata": {}, "score": "51.364662"}
{"text": "More than two - thirds ( 67 % ) of the participants gave the reason of having a robust clinical data behind their choice of therapy , while one - third stated concerns regarding safety as their primary motivation behind the choice of the agent of their preference .", "label": "", "metadata": {}, "score": "51.579277"}
{"text": "View Article .Verpoest WM , Kolibianakis E , Papanikolaou E , Smitz J , Van SA , Devroey P : Aromatase inhibitors in ovarian stimulation for IVF / ICSI : a pilot study .", "label": "", "metadata": {}, "score": "51.709476"}
{"text": "66 - 84 , 2011 .View at Publisher \u00b7 View at Google Scholar .R. C. Coombes , E. Hall , L. J. Gibson et al . , \" A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "51.7472"}
{"text": "A well - designed and powered randomized clinical trial will be needed to confirm this result .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "51.977154"}
{"text": "10.1056/NEJMoa040331 PubMed View Article .J Clin Oncol 2012 , 30 : 709 - 717 .10.1200/JCO.2010.33.7899 PubMed View Article .Kaufmann M , Jonat W , Hilfrich J , Eidtmann H , Gademann G , Zuna I , von Minckwitz G : Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen : the ARNO 95 Study .", "label": "", "metadata": {}, "score": "52.066414"}
{"text": "A randomized clinical trial involving 2,021 post - menopausal women receiving tamoxifen alone for 5 years or in combination with AG for the first 2 years of treatment showed no significant difference in 5-year DFS and OS [ 38 ] .", "label": "", "metadata": {}, "score": "52.152298"}
{"text": "Studies of postmenopausal women with breast cancer receiving adjuvant AI therapy treated concurrently with an osteoblast inhibitor have shown the ability to maintain bone loss .", "label": "", "metadata": {}, "score": "52.23053"}
{"text": "This enzyme is effectively blocked by the third - generation aromatase inhibitors .The third - generation aromatase inhibitors first made their impact when they were compared to megestrol acetate in metastatic breast cancer ( MBC ) setting and showed superior time to progression ( TTP ) [ 13 ] .", "label": "", "metadata": {}, "score": "52.337624"}
{"text": "Of the 8 meta - analyses done on each subject for publication bias , only one study showed publication bias between the studies , that is , the 12-month LS BMD analysis of patients who had a normal BMD at baseline .", "label": "", "metadata": {}, "score": "52.461994"}
{"text": "AIMSS , aromatase inhibitor - associated musculoskeletal symptoms ; TCM , traditional Chinese medicine ; YSJG , Yi Shen Jian Gu granules .Ethical issues .", "label": "", "metadata": {}, "score": "52.652946"}
{"text": "View Article PubMed .Neveu NGL , St.-Michel P , Lavoie HB : Comparison of clomiphene citrate , metformin , or the combination of both for first - line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome .", "label": "", "metadata": {}, "score": "52.662033"}
{"text": "NCIC CTG MA.17/BIG 1 - 97 .NCIC CTG MA.17/BIG 1 - 97 tested the effectiveness of 5 years of letrozole after completion of the standard 4 to 6 years of adjuvant tamoxifen and was the first phase III trial to demonstrate an OS advantage with an adjuvant AI [ 50 ] .", "label": "", "metadata": {}, "score": "52.749195"}
{"text": "19 , 20 ] .The existing and evolving knowledge and research on refinement in hormonal therapy for postmenopausal women generally is favoring the use of AIs , a longer duration of therapy and possibly for using the agents alternatively .", "label": "", "metadata": {}, "score": "52.79858"}
{"text": "There was no statistically significant difference in OS between the two arms .NSABP - B33 investigated extended adjuvant therapy with exemestane in post - menopausal women with clinical T1 - 3N1M0 BC who were disease - free after 5 years of adjuvant tamoxifen [ 52 ] .", "label": "", "metadata": {}, "score": "52.943645"}
{"text": "12 , pp .2893 - 2917 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Coombes , L. Kilburn , C. Snowdon et al . , \" Survival and safety of exemestane versus tamoxifen after 2 - 3 years ' tamoxifen treatment ( Intergroup Exemestane Study ) : a randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "52.947918"}
{"text": "Goss PE , Ingle JN , Martino S et al ( 2003 )A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early - stage breast cancer .", "label": "", "metadata": {}, "score": "53.009544"}
{"text": "Comparison of the aromatase inhibitors letrozole and anastrozole .Eur J Cancer 39:2318 - 2327 PubMed CrossRef .Garreau JR , Delamelena T , Walts D et al ( 2006 )", "label": "", "metadata": {}, "score": "53.22569"}
{"text": "Breast international group 1 - 98 .The BIG 1 - 98 study involved the other third - generation non - steroidal AI , letrozole , and compared 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one of these agents followed by 3 years of the other .", "label": "", "metadata": {}, "score": "53.234203"}
{"text": "These findings must be interpreted with caution because of the small sample size and use of a cross - sectional design .A prospective analysis from BIG 1 - 98 showed that cognitive function was significantly better among patients on letrozole versus tamoxifen at the end of the 5-year treatment period [ 88 ] .", "label": "", "metadata": {}, "score": "53.497295"}
{"text": "However , the trial 's weaknesses include that it was not double blinded ; there was no information on Her2 status ; and it was underpowered for the endocrine question .", "label": "", "metadata": {}, "score": "53.741596"}
{"text": "10.1016/S1028 - 4559(10)60064 - 2 .View Article .Schoolcraft WB , Surrey ES , Minjarez DA , Stevens JM , Gardner DK : Management of poor responders : can outcomes be improved with a novel gonadotropin - releasing hormone antagonist / letrozole protocol ?", "label": "", "metadata": {}, "score": "53.74851"}
{"text": "The results of this study will provide a new evidence - based treatment strategy for patients suffering from AIMSS .Trial status .Abbreviations .Aromatase inhibitor - associated musculoskeletal symptoms .", "label": "", "metadata": {}, "score": "53.776665"}
{"text": "Luteal phase aromatase inhibitors .The first randomized pilot study assessing the effect of administration of letrozole during the luteal phase of stimulated IVF cycles in oocyte donors was published in 2008 [ 14 ] .", "label": "", "metadata": {}, "score": "53.795612"}
{"text": "PubMed View Article .Din OS , Dodwell D , Wakefield RJ , Coleman RE : Aromatase inhibitor - induced arthralgia in early breast cancer : what do we know and how can we find out more ?", "label": "", "metadata": {}, "score": "53.825787"}
{"text": "P 4 showed no differences between any treatment groups .Table 2 .Hormonal dynamics : follicular phase levels of serum estradiol , progesterone , and LH .", "label": "", "metadata": {}, "score": "54.0959"}
{"text": "The important questions of which patients really benefit and whether extended adjuvant endocrine therapy should be with tamoxifen or an AI in post - menopausal women currently remain unanswered .", "label": "", "metadata": {}, "score": "54.107185"}
{"text": "The authors demonstrated a significant improvement in DFS and RFS with the addition of ZOL to endocrine therapy .The authors have done an excellent job in designing and implementing a large enough study to evaluate this question .", "label": "", "metadata": {}, "score": "54.202656"}
{"text": "Mauri D , Pavlidis N , Polyzos NP et al ( 2006 ) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer : meta - analysis .", "label": "", "metadata": {}, "score": "54.269676"}
{"text": "Therefore , 34 participants per group were deemed sufficient to achieve 90 % power and a ( one - sided ) 5 % significance level in detecting treatment differences .", "label": "", "metadata": {}, "score": "54.29883"}
{"text": "No clear data is available regarding the use of AI 's in premenopausal women .A comparison of TAM and ANA in premenopausal patients in a large randomized trial is warranted .", "label": "", "metadata": {}, "score": "54.31552"}
{"text": "10.1016/j.fertnstert.2007.08.060 .View Article PubMed .Hamilton A , Piccart M : The third - generation non - steroidal aromatase inhibitors : a review of their clinical benefits in the second - line hormonal treatment of advanced breast cancer .", "label": "", "metadata": {}, "score": "54.465874"}
{"text": "In post - menopausal women , AIs are significantly more effective than tamoxifen in preventing recurrence but so far only letrozole has been shown to have survival benefit .", "label": "", "metadata": {}, "score": "54.510315"}
{"text": "[ 2 ] .Apart from AIs being regarded as part of routine adjuvant therapy for postmenopausal breast cancer patients , they are being studied in combination with ovarian suppression in premenopausal breast cancer patients and even for prevention .", "label": "", "metadata": {}, "score": "54.735123"}
{"text": "has given a precise estimate of musculoskeletal disorders of zoledronic acid in adjuvant breast cancer treatment [ 1 ] .But , these meta - analyses have chosen overall survival , disease free survival or recurrence free survival as their endpoints .", "label": "", "metadata": {}, "score": "54.788258"}
{"text": "PubMed Central View Article .Garcia - Velasco JA , Moreno L , Pacheco A , Guillen A , Duque L , Requena A , Pellicer A : The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients : a pilot study .", "label": "", "metadata": {}, "score": "54.79134"}
{"text": "About 8 % stated that a trustworthy pharmaceutical company was the major factor behind the decision regarding the drug of their choice .Figure 2 summarizes the reason considered for prescription by different physicians .", "label": "", "metadata": {}, "score": "54.864082"}
{"text": "PubMed View Article .Greenlee H , Crew KD , Shao T , Kranwinkel G , Kalinsky K , Maurer M , Brafman L , Insel B , Tsai WY , Hershman DL : Phase II study of glucosamine with chondroitin on aromatase inhibitor - associated joint symptoms in women with breast cancer .", "label": "", "metadata": {}, "score": "54.97534"}
{"text": "10.1210/jc.2007 - 0247 .View Article .Oktay K , Turkcuoglu I , Rodriguez - Wallberg KA : GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor / FSH stimulation .", "label": "", "metadata": {}, "score": "55.026115"}
{"text": "J Bone Miner Res 9:1137 - 1141 CrossRef PubMed .Eastell R , Hannon RA , Cuzick J et al ( 2006 )Effect of an aromatase inhibitor on BMD and bone turnover markers : 2-year results of the Anastrozole , Tamoxifen , Alone or in Combination ( ATAC ) trial ( 18233230 ) .", "label": "", "metadata": {}, "score": "55.13764"}
{"text": "PubMed .Geisler J , Haynes B , Anker G , Dowsett M , Lonning PE : Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized , cross - over study .", "label": "", "metadata": {}, "score": "55.14608"}
{"text": "10.1016/j.fertnstert.2007.02.013 .View Article .Fatemi HM , Popovic - Todorovic B , Donoso P , Papanikolaou E , Smitz J , Devroey P : Luteal phase oestradiol suppression by letrozole : a pilot study in oocyte donors .", "label": "", "metadata": {}, "score": "55.20806"}
{"text": "J Natl Cancer Inst 97:1262 - 1271 CrossRef PubMed .Smith IE , Dowsett M ( 2003 ) Aromatase inhibitors in breast cancer .N Engl J Med 348:2431 - 2442 CrossRef PubMed .", "label": "", "metadata": {}, "score": "55.244698"}
{"text": "Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors Abstract .Aromatase inhibitors have been introduced as a new treatment modality that could challenge clomiphene citrate as an ovulation induction regiment in patients with PCOS .", "label": "", "metadata": {}, "score": "55.262783"}
{"text": "M. Gnant , B. Mlineritsch , G. Luschin - Ebengreuth et al . , \" Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early - stage breast cancer : 5-year follow - up of the ABCSG-12 bone - mineral density substudy , \" The Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "55.34048"}
{"text": "The first small randomized trial published in 2004 examined the use of letrozole as part of a low - cost IVF protocol for poor responders .", "label": "", "metadata": {}, "score": "55.388084"}
{"text": "In ER + disease , there were nine deaths in the tamoxifen group and one in the control group from uterine cancer and six versus no deaths from pulmonary embolus ( PE ) during the first 5 years ( but no apparent excess afterwards ) .", "label": "", "metadata": {}, "score": "55.395462"}
{"text": "Observational studies , however , have shown that aromatase inhibitor - associated musculoskeletal symptoms ( AIMSS ) are more prevalent than originally reported [ 9 , 10 ] .", "label": "", "metadata": {}, "score": "55.480843"}
{"text": "Patients completed the Health Assessment Questionnaire ( HAQ ) and Visual Analog Scale ( VAS ) at baseline , 1 , 3 , 6 , and 12 months to assess changes in function and pain , respectively .", "label": "", "metadata": {}, "score": "55.487053"}
{"text": "Ann Oncol 20:1489 - 1498 CrossRef PubMed .Coombes RC , Hall E , Gibson LJ ( 2004 )A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer .", "label": "", "metadata": {}, "score": "55.51445"}
{"text": "View Article PubMed .Badawy A , Elnashar A , Totongy M : Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination : a prospective randomized trial .", "label": "", "metadata": {}, "score": "55.547386"}
{"text": "PubMed View Article .Kubo M , Onishi H , Kuroki S , Okido M , Shimada K , Yokohata K , Umeda S , Ogawa T , Tanaka M , Katano M : Short - term and low - dose prednisolone administration reduces aromatase inhibitor - induced arthralgia in patients with breast cancer .", "label": "", "metadata": {}, "score": "55.55841"}
{"text": "In postmenopausal women with breast cancer , AI causes complete suppression of aromatase activity and decrease in the level of circulating oestrogen concentrations .Therefore , the postmenopausal patients receiving aromatase inhibitors are having a high risk of bone loss which will impact their quality of life [ 7 , 8 ] .", "label": "", "metadata": {}, "score": "55.568382"}
{"text": "10.1023/B : BREA.0000025406.31193 . e8 PubMed View Article .Stearns V , Johnson MD , Rae JM , Morocho A , Novielli A , Bhargava P , Hayes DF , Desta Z , Flockhart DA : Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine .", "label": "", "metadata": {}, "score": "55.58326"}
{"text": "Freedman AN , Yu B , Gail MH et al ( 2011 )Benefit / Risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older .", "label": "", "metadata": {}, "score": "55.62181"}
{"text": "View at Publisher \u00b7 View at Google Scholar .J. M. S. Bartlett , D. Rea , and D. L. Rimm , \" Quantification of hormone receptors to guide adjuvant therapy choice in early breast cancer : better methods required for improved utility , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.644238"}
{"text": "Unexplained infertility was based on the exclusion of known factors of infertility .Cycle monitoring and insemination .All patients were followed with serial measurements of serum estradiol ( E 2 ) , progesterone ( P 4 ) , and luteinizing hormone ( LH ) using a radioimmunoassay ( RIA ) kit .", "label": "", "metadata": {}, "score": "55.650665"}
{"text": "3803 , pp .162 - 165 , 1896 .View at Google Scholar \u00b7 View at Scopus .M. Nadji , C. Gomez - Fernandez , P. Ganjei - Azar , and A. R. Morales , \" Immunohistochemistry of estrogen and progesterone receptors reconsidered : experience with 5,993 breast cancers , \" American Journal of Clinical Pathology , vol .", "label": "", "metadata": {}, "score": "55.668243"}
{"text": "In addition , investigators will ask every subject at each visit whether they have experienced any adverse events ( AEs ) during the study period .", "label": "", "metadata": {}, "score": "55.742508"}
{"text": "Breast Cancer 13:284 - 288 PubMed CrossRef .Felson DT , Cummings SR ( 2005 ) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation .", "label": "", "metadata": {}, "score": "55.758614"}
{"text": "Buzdar A , Howell A , Cuzick J et al ( 2006 )Comprehensive side - effect profile of anastrozole and tamoxifen as adjuvant treatment for early - stage breast cancer : long - term safety analysis of the ATAC trial .", "label": "", "metadata": {}, "score": "55.81102"}
{"text": "5 , pp .1001 - 1010 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. van Poznak , R. A. Hannon , J. R. Mackey et al . , \" Prevention of aromatase inhibitor - induced bone loss using risedronate : the SABRE trial , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.824066"}
{"text": "In this systematic review and meta - analysis , a total of 2772 postmenopausal patients with breast cancer were included .The pooled odds ratio and standard mean difference with 95 % CI indicated that third - generation bisphosphonate therapy was associated with significant improvement in the BMD .", "label": "", "metadata": {}, "score": "55.858173"}
{"text": "10.1016/S0140 - 6736(10)62312 - 4 PubMed View Article .Jin H , Tu D , Zhao N , Shepherd LE , Goss PE : Longer - term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial : analyses adjusting for treatment crossover .", "label": "", "metadata": {}, "score": "55.858246"}
{"text": "Of the 26 studies identified by database searching , 7 duplicates were removed , and 7 trials were removed on the basis of the title and abstract themselves .", "label": "", "metadata": {}, "score": "55.91806"}
{"text": "Although our systematic review included 6 RCTs , the subgroup meta - analysis was based on a smaller number of studies , and the evidence could have been stronger if the number was bigger .", "label": "", "metadata": {}, "score": "55.955536"}
{"text": "10.1093/jnci / djs126 PubMed Central PubMed View Article .Nakamura Y , Ratain MJ , Cox NJ , McLeod HL , Kroetz DL , Flockhart DA : Re : CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine - responsive breast cancer : the Breast International Group 1 - 98 trial .", "label": "", "metadata": {}, "score": "55.95967"}
{"text": "Both had a significant decrease in BMD that favoured the delayed ZOL ; 3 trials of risedronate and ibandronate also had a significant decrease in BMD in AIs alone group .", "label": "", "metadata": {}, "score": "56.072426"}
{"text": "Introduction .Adjuvant endocrine therapy , usually today with tamoxifen or an aromatase inhibitor ( AI ) , is standard treatment for estrogen receptor - positive ( ER + ) , early - stage breast cancer ( BC ) , which accounts for approximately 75 % of BC [ 1 ] .", "label": "", "metadata": {}, "score": "56.27079"}
{"text": "10.1056/NEJM198109033051003 PubMed View Article .Jones AL , Powles TJ , Law M , Tidy A , Easton D , Coombes RC , Smith IE , McKinna JA , Nash A , Ford HT , Gazet JC : Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer : analysis at 8 years .", "label": "", "metadata": {}, "score": "56.416412"}
{"text": "Abstract .The choice of adjuvant hormonal therapy in postmenopausal women with hormone receptor positive breast cancer has remained a matter of controversy and debate .", "label": "", "metadata": {}, "score": "56.475967"}
{"text": "In the case of serious adverse events ( SAEs ) , the investigator will offer appropriate treatment to the subject immediately and report the event to the Institutional Review Board within 24 hours from the time of recognition .", "label": "", "metadata": {}, "score": "56.49301"}
{"text": "Goss PE , Strasser - Weippl K ( 2004 )Prevention strategies with aromatase inhibitors .Clin Cancer Res 10:372S-379S CrossRef PubMed .Coleman RE , Banks LM , Girgis SI ( 2010 ) Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study .", "label": "", "metadata": {}, "score": "56.591087"}
{"text": "PubMed View Article .Crew KD , Capodice JL , Greenlee H , Brafman L , Fuentes D , Awad D , Yann TW , Hershman DL : Randomized , blinded , sham - controlled trial of acupuncture for the management of aromatase inhibitor - associated joint symptoms in women with early - stage breast cancer .", "label": "", "metadata": {}, "score": "56.607502"}
{"text": "However , useful empirical observation is insufficient .Therefore , there is a need for a well - designed clinical trial to investigate the efficacy and safety of YSJG on AIMSS .", "label": "", "metadata": {}, "score": "56.628716"}
{"text": "6 , pp .967 - 975 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. E. Lester , D. Dodwell , O. P. Purohit et al . , \" Prevention of anastrozole - induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.74505"}
{"text": "After a median follow - up of 120 months , the long - term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy were confirmed [ 53 ] .", "label": "", "metadata": {}, "score": "56.792717"}
{"text": "Several ongoing studies are investigating extended AIs in regard to optimal duration , intermittent versus continuous use , and benefit after AIs used during the first 5 years of therapy ( Table 5 ) [ 108 ] . a Including as part of MA.17 .", "label": "", "metadata": {}, "score": "56.801514"}
{"text": "Winer EP , Hudis C , Burstein HJ et al ( 2005 ) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor - positive breast cancer : status report 2004 .", "label": "", "metadata": {}, "score": "56.80199"}
{"text": "10.1038/nm1202 - 1341 PubMed View Article .Smith IE , Dowsett M : Aromatase inhibitors in breast cancer .N Engl J Med 2003 , 348 : 2431 - 2442 .", "label": "", "metadata": {}, "score": "56.847794"}
{"text": "Rae JM , Drury S , Hayes DF , Stearns V , Thibert JN , Haynes BP , Salter J , Sestak I , Cuzick J , Dowsett M : CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen - treated breast cancer patients .", "label": "", "metadata": {}, "score": "56.92836"}
{"text": "PubMed View Article .Cuzick J , Ambroisine L , Davidson N , Jakesz R , Kaufmann M , Regan M , Sainsbury R : Use of luteinising - hormone - releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone - receptor - positive breast cancer : a meta - analysis of individual patient data from randomised adjuvant trials .", "label": "", "metadata": {}, "score": "56.955723"}
{"text": "Table 1 .Main prospective , randomized , phase III clinical trials testing adjuvant aromatase inhibitors .Table 2 .Outcome results in the main phase III clinical trials testing adjuvant aromatase inhibitors .", "label": "", "metadata": {}, "score": "57.049034"}
{"text": "Administration of 2.5 mg letrozole for 5 days from the day of ovum pick - up , significantly reduced serum E2 levels at 4 , 7 and 10 days after oocyte retrieval compared to placebo in accordance to the study by Fatemi et al .", "label": "", "metadata": {}, "score": "57.16416"}
{"text": "10.1007/s00404 - 008 - 0714 - 4 .View Article PubMed .Al - Fozan H , Al - Khadouri M , Tan SL , Tulandi T : A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation .", "label": "", "metadata": {}, "score": "57.1669"}
{"text": "The Austrian Breast and Colorectal Cancer Study Group Trial 12 ( ABCSG-12 ) was undertaken to examine the efficacy of goserelin in combination with ANA or TAM + /- ZOL in pre - menopausal women with hormone receptor - positive breast cancer .", "label": "", "metadata": {}, "score": "57.181442"}
{"text": "However , most of these trials have had some methodological and practical limitations , including small sample sizes , larger - than - anticipated drop - out , a single - center design , lack of control group and blinding , and a short follow - up period .", "label": "", "metadata": {}, "score": "57.39125"}
{"text": "IVI , Valencia , Plaza de la Polic\u00eda , .References .Mauri D , Pavlidis N , Polyzos NP , Ioannidis JP : Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer : meta - analysis .", "label": "", "metadata": {}, "score": "57.51654"}
{"text": "Ellis GK , Bone HG , Chlebowski R et al ( 2009 )Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non - metastatic breast cancer : subgroup analyses of a phase 3 study .", "label": "", "metadata": {}, "score": "57.606415"}
{"text": "N Engl J Med 1988 , 319 : 1681 - 1692 .View Article .Early Breast Cancer Trialists ' Collaborative Group ( EBCTCG ) : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials .", "label": "", "metadata": {}, "score": "57.61245"}
{"text": "19 , pp .6336 - 6342 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Markopoulos , E. Tzoracoleftherakis , A. Polychronis et al . , \" Management of anastrozole - induced bone loss in breast cancer patients with oral risedronate : results from the ARBI prospective clinical trial , \" Breast Cancer Research , vol .", "label": "", "metadata": {}, "score": "57.651257"}
{"text": "The results favoured the bisphosphonates + placebo group for decrease in BMD value compared with bisphosphonates + AIs , indicating that the bisphosphonates favour an increase in BMD .", "label": "", "metadata": {}, "score": "57.657913"}
{"text": "Lancet 2007 , 369 : 559 - 570 .PubMed View Article .Updated results of the Italian tamoxifen anastrozole ( ITA ) trial .Ann Oncol 2006 , 17 ( 7):i10-i14 .", "label": "", "metadata": {}, "score": "57.707287"}
{"text": "However , the pregnancy rate is [ 2 ] disappointing .Newer options for ovulation induction are the third - generation aromatase inhibitors ( AIs ) , the most commonly used being letrozole .", "label": "", "metadata": {}, "score": "57.717186"}
{"text": "Affiliated with .Abstract .Adjuvant endocrine therapy reduces the risk of recurrence and death from breast cancer in women with hormone receptor - positive early breast cancer .", "label": "", "metadata": {}, "score": "57.80945"}
{"text": "Cummings SR , Duong T , Kenyon E et al ( 2002 ) Serum estradiol level and risk of breast cancer during treatment with raloxifene .", "label": "", "metadata": {}, "score": "57.85437"}
{"text": "N Engl J Med 1989 , 320 : 479 - 484 .10.1056/NEJM198902233200802 PubMed View Article .Fisher B , Jeong JH , Bryant J , Anderson S , Dignam J , Fisher ER , Wolmark N : Treatment of lymph - node - negative , oestrogen - receptor - positive breast cancer : long - term findings from national surgical adjuvant breast and bowel project randomised clinical trials .", "label": "", "metadata": {}, "score": "57.97557"}
{"text": "This trial was registered with ISRCTN at Current Controlled Trials ( ISRCTN06129599 ) .Study participants .Participants will be recruited from three hospitals ( Beijing Hospital of Traditional Chinese Medicine , Beijing Cancer Hospital , and Guang ' Anmen Hospital ) by poster and website advertisements .", "label": "", "metadata": {}, "score": "58.0076"}
{"text": "40 - 48 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Brufsky , W. G. Harker , J. T. Beck et al . , \" Zoledronic acid inhibits adjuvant letrozole - induced bone loss in postmenopausal women with early breast cancer , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "58.101494"}
{"text": "9561 , pp .559 - 570 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Biganzoli , S. Licitra , W. Claudino , M. Pestrin , and A. D. Leo , \" Clinical decision making in breast cancer : TAM and aromatase inhibitors for older patients - a jungle ? \" European Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "58.136177"}
{"text": "10.1002/pon.709 PubMed View Article .Bender CM , Sereika SM , Brufsky AM , Ryan CM , Vogel VG , Rastogi P , Cohen SM , Casillo FE , Berga SL : Memory impairments with adjuvant anastrozole versus tamoxifen in women with early - stage breast cancer .", "label": "", "metadata": {}, "score": "58.219948"}
{"text": "Aromatase - deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren 's syndrome .Proc Natl Acad Sci U S A 101:12628 - 12633 PubMed CrossRef .", "label": "", "metadata": {}, "score": "58.306618"}
{"text": "10.1002/sim.2128 PubMed View Article .Robins JM , Finkelstein DM : Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted ( IPCW ) log - rank tests .", "label": "", "metadata": {}, "score": "58.374348"}
{"text": "Eastell R , Adams J , Clack G et al ( 2011 )Long - term effects of anastrozole on bone mineral density : 7-year results from the ATAC trial .", "label": "", "metadata": {}, "score": "58.374977"}
{"text": "10.1016/j.fertnstert.2004.04.070 .View Article PubMed .Barroso G , Menocal G , Felix H , Rojas - Ruiz JC , Arslan M , Oehninger S : Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle - stimulating hormone in controlled ovarian hyperstimulation : a prospective , randomized , blinded clinical trial .", "label": "", "metadata": {}, "score": "58.38851"}
{"text": "4 , pp .276 - 281 , 2012 .View at Google Scholar . A. T. Stopeck , A. Lipton , J.-J. Body et al . , \" Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized , double - blind study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "58.4488"}
{"text": "However , aromatase inhibitor therapy increase bone turnover as a result of nearly complete oestrogen depletion , leading to increases in bone loss and fragility fractures that erode the patient 's functional independence and quality of life .", "label": "", "metadata": {}, "score": "58.469063"}
{"text": "10.1146/annurev.pa.35.040195.001211 PubMed View Article .Johnson MD , Zuo H , Lee KH , Trebley JP , Rae JM , Weatherman RV , Desta Z , Flockhart DA , Skaar TC : Pharmacological characterization of 4-hydroxy - N - desmethyl tamoxifen , a novel active metabolite of tamoxifen .", "label": "", "metadata": {}, "score": "58.474182"}
{"text": "The mechanism of action of AIs relies on the fact that most estrogen in the postmenopausal women comes from conversion of steroid hormones to estrogen .", "label": "", "metadata": {}, "score": "58.51509"}
{"text": "Gnant M , Mlineritsch B , Luschin - Ebengreuth G et al ( 2008 )Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early - stage breast cancer : 5-year follow - up of the ABCSG-12 bone - mineral density substudy .", "label": "", "metadata": {}, "score": "58.551727"}
{"text": "This 94 % DFS rate and 98.2 % OS rate at 5 years for the overall trial are reassuring , but may also have been the reason why the endocrine question was unable to be answered .", "label": "", "metadata": {}, "score": "58.71601"}
{"text": "Interventions .Because the formula for YSJG is currently being patented , the ingredients in YSJG can not be published at this time .For the control group , placebo granules are made from dextrin ( 95 % ) and Herba pogostemonis ( 5 % ) in order to achieve the same color , smell , taste , and texture as that of YSJG granules .", "label": "", "metadata": {}, "score": "58.721176"}
{"text": "Patients .The study included 208 patients who underwent a total of 300 consecutive IUI cycles .There were 71 cycles in the natural cycle group , 179 cycles in the letrozole 2.5 mg / day group , and 50 cycles in the letrozole 5 mg / day group ( table 1 ) .", "label": "", "metadata": {}, "score": "58.726795"}
{"text": "Physicians show disagreement over the choice and duration of hormonal therapy in this patient population .Clinical trials leading to firm recommendations to set standards from which patients benefit the most are needed .", "label": "", "metadata": {}, "score": "58.783012"}
{"text": "\" 63.7 % responding physicians said yes while 33 % replied in negative .Amongst the physicians who switched to another agent 67.2 % based their decisions on presence of data , and 24 % had to switch the therapy due to problems encountered during the patient management .", "label": "", "metadata": {}, "score": "58.823402"}
{"text": "10.1016/S0140 - 6736(07)60200 - 1 PubMed View Article .Dent SF , Gaspo R , Kissner M , Pritchard KI : Aromatase inhibitor therapy : toxicities and management strategies in the treatment of postmenopausal women with hormone - sensitive early breast cancer .", "label": "", "metadata": {}, "score": "58.856537"}
{"text": "10.1016/j.fertnstert.2005.01.139 .View Article .Tulandi T , Martin J , Al - Fadhli R , Kabli N , Forman R , Hitkari J , Librach C , Greenblatt E , Casper RF : Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate .", "label": "", "metadata": {}, "score": "58.858376"}
{"text": "So , the contribution of each for getting an overall summary effect was relatively equal ( Figure 2 ) .Bone Mineral Density Analysis for SABRE , ARIBON , and ARBI Trials .", "label": "", "metadata": {}, "score": "58.8657"}
{"text": "Study Group .Osteoporos Int 11:83 - 91 CrossRef PubMed .Ettinger B , Black DM , Mitlak BH et al ( 1999 ) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial .", "label": "", "metadata": {}, "score": "58.88293"}
{"text": "Gnant M , Mlineritsch B , Schippinger W et al ( 2009 ) Endocrine therapy plus zoledronic acid in premenopausal breast cancer .N Engl J Med 360:679 - 691 CrossRef PubMed .", "label": "", "metadata": {}, "score": "58.939205"}
{"text": "Servitja S , Nogu\u00e9s X , Prieto - Alhambra D et al , Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer .", "label": "", "metadata": {}, "score": "58.964447"}
{"text": "2003 , 80 ( 6 ) : 1338 - 10.1016/j.fertnstert.2003.06.001 .View Article .Sim\u00f3n CCF , Valbuena D , Remoh\u00ed J , Pellicer A : Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients .", "label": "", "metadata": {}, "score": "58.983894"}
{"text": "10 , pp .475 - 482 , 2007 .View at Google Scholar \u00b7 View at Scopus .J. J. Body , I. J. Diel , M. Liehinitzer et al . , \" Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease : results from two randomised , placebo - controlled phase III studies , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "59.008846"}
{"text": "View Article PubMed .Begum MR , Ferdous J , Begum A , Quadir E : Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome .", "label": "", "metadata": {}, "score": "59.0235"}
{"text": "References .Perez EA , Weilbaecher K ( 2006 ) Aromatase inhibitors and bone loss .Oncology 20(9):1029 - 1039 PubMed .Powles T , Hickish T , Kanis JA , Tidy A , Ashley S ( 1996 )", "label": "", "metadata": {}, "score": "59.075684"}
{"text": "These results showed that letrozole improved DFS and TTDR versus tamoxifen alone .After a median follow - up of 25.8 months , 5-year DFS estimates were 84.0 % and 81.4 % , respectively .", "label": "", "metadata": {}, "score": "59.173782"}
{"text": "10.1016/j.fertnstert.2005.01.117 .View Article .Polyzos NP , Tsappi M , Mauri D , Atay V , Cortinovis I , Casazza G : Aromatase inhibitors for infertility in polycystic ovary syndrome .", "label": "", "metadata": {}, "score": "59.22163"}
{"text": "Both randomized trials provided evidence that letrozole drastically reduces E2 levels whereas the trial Garcia - Velasco et al . , demonstrated that letrozole restores LH secretion sooner in egg donors .", "label": "", "metadata": {}, "score": "59.237774"}
{"text": "Methods .A panel of experts addressed the issue of skeletal effects of AIs and effectiveness of antifracture therapies for the prevention of AI - induced bone loss and fractures .", "label": "", "metadata": {}, "score": "59.263145"}
{"text": "Nonetheless , no difference in LH levels was observed among treatment and control groups ( Table 2 ) .Table 2 .Available randomized trials regarding the use of letrozole during the luteal phase in oocyte donors .", "label": "", "metadata": {}, "score": "59.26468"}
{"text": "Results .All aromatase inhibitors are associated with negative effects on the skeleton , resulting in bone loss and increased risk of fragility fractures .Current guidelines suggest approaches that differ both in terms of drugs proposed for fracture prevention and duration of treatment .", "label": "", "metadata": {}, "score": "59.394844"}
{"text": "Cummings SR , Black DM , Thompson DE et al ( 1998 )Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Trial .", "label": "", "metadata": {}, "score": "59.396477"}
{"text": "Coates AS , Keshaviah A , Thurlimann B et al ( 2007 )Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine - responsive early breast cancer : update of study BIG 1 - 98 .", "label": "", "metadata": {}, "score": "59.453484"}
{"text": "( i ) Observational studies and case control studies , ( ii ) Quasirandomised trials , ( iii ) Unpublished literature , ( iv ) RCTs published in abstracts , ( v )", "label": "", "metadata": {}, "score": "59.645393"}
{"text": "Only 30 % of patients were node positive .At a median follow up of 60 months in March 2008 , 137 ( 7.6 % ) DFS events and 42 ( 2.3 % ) deaths occurred .", "label": "", "metadata": {}, "score": "59.6709"}
{"text": "10.1097/OGX.0b013e31817d4e8d .View Article .Polyzos NP , Tzioras S , Badawy AM , Valachis A , Dritsas C , Mauri D : Aromatase inhibitors for female infertility : a systematic review of the literature .", "label": "", "metadata": {}, "score": "59.716255"}
{"text": "All third - generation compounds approach nearly complete suppression of total - body aromatization and plasma estrogen levels [ 40 , 41 ] .In a recent study , letrozole was found to inhibit whole - body aromatization by greater than 99 % in all 12 patients [ 41 ] .", "label": "", "metadata": {}, "score": "59.72091"}
{"text": "10.1093/jnci / djg108 PubMed View Article .Pharoah PD , Abraham J , Caldas C : Re : CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine - responsive breast cancer : the breast international group 1 - 98 trial and Re : CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen - treated breast cancer patients .", "label": "", "metadata": {}, "score": "59.810112"}
{"text": "Of note , similar baseline BMD in the two groups and the use of bisphosphonate therapy both before and during the study were reported in this study .", "label": "", "metadata": {}, "score": "59.941055"}
{"text": "About this Article .Title .Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer : an ESCEO position paper Abstract .", "label": "", "metadata": {}, "score": "59.981453"}
{"text": "PubMed View Article .Davidson NE , O'Neill AM , Vukov AM , Osborne CK , Martino S , White DR , Abeloff MD : Chemoendocrine therapy for premenopausal women with axillary lymph node - positive , steroid hormone receptor - positive breast cancer : results from INT 0101 ( E5188 ) .", "label": "", "metadata": {}, "score": "60.037235"}
{"text": "Different analytical tools were developed to overcome this , including inverse probability of censoring weighted ( IPCW ) analysis , which achieves better estimates of relative treatment effects in the presence of selective crossover [ 58 , 59 ] .", "label": "", "metadata": {}, "score": "60.04959"}
{"text": "This clinical survey was undertaken to get an impression of the physician 's first choice of therapy in an attempt to find out what questions still need to be answered in the making of \" standard of care .", "label": "", "metadata": {}, "score": "60.07256"}
{"text": "Therefore any use is off - label .Conclusions .Current evidence supports aromatase inhibitors can be a safe solution for fertility preservation in cancer patients prior chemotherapy .", "label": "", "metadata": {}, "score": "60.126022"}
{"text": "Fertil Steril .10.1016/j.fertnstert.2007.10.016 .View Article .Polyzos NP , Tzioras S , Mauri D , Tsappi M , Cortinovis I , Tsali L , Casazza G : Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "60.159256"}
{"text": "Gnant M , Mlineritsch B , Luschin - Ebengreuth G ( 2008 )Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early - stage breast cancer : 5-year follow - up of the ABCSG-12 bone - mineral density substudy .", "label": "", "metadata": {}, "score": "60.181026"}
{"text": "The Adjuvant post - Tamoxifen Exemestane versus Nothing Applied trial compared exemestane versus observation after 5 years of previous tamoxifen [ 106 ] .This trial was prematurely closed after recruiting only 448 patients .", "label": "", "metadata": {}, "score": "60.290802"}
{"text": "Nodal status , tumor grade , and diameter did not materially affect proportional risk reductions , but they were of course predictive of the absolute risk without tamoxifen and hence of the absolute benefit .", "label": "", "metadata": {}, "score": "60.393272"}
{"text": "Only few randomized trials , with limited series of patients , have been conducted up to date and the main research interest has been accumulated in the effect of letrozole in the treatment of poor responders .", "label": "", "metadata": {}, "score": "60.487076"}
{"text": "Our survey clearly demonstrates the discord that is seen in general amongst the treating physicians .Although our survey has limitations in the form of number of participants and geographical variance to claim global representation ; we , nevertheless , find that Tamoxifen is still prescribed as frequently in postmenopausal women with early stage breast cancer in adjuvant setting as are AIs .", "label": "", "metadata": {}, "score": "60.525326"}
{"text": "Eastell R , Adams JE , Coleman RE , Howell A , Hannon RA , Cuzick J , Mackey JR , Beckmann MW , Clack G : Effect of anastrozole on bone mineral density : 5-year results from the anastrozole , tamoxifen , alone or in combination trial 18233230 .", "label": "", "metadata": {}, "score": "60.563713"}
{"text": "References .W. W. Huang , C. Huang , J. Liu , H. Y. Zheng , and L. Lin , \" Zoledronic acid as an adjuvant therapy in patients with breast cancer : a systematic review and meta - analysis , \" PloS ONE , vol .", "label": "", "metadata": {}, "score": "60.628586"}
{"text": "10.1016/j.fertnstert.2008.06.013 .View Article PubMed .Sh Tehrani Nejad E , Abediasl Z , Rashidi BH , Azimi Nekoo E , Shariat M , Amirchaghmaghi E : Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation : a prospective , simply randomized , clinical trial .", "label": "", "metadata": {}, "score": "60.652466"}
{"text": "View Article .Early Breast Cancer Trialists ' Collaborative Group : Tamoxifen for early breast cancer : an overview of the randomised trials .Lancet 1998 , 351 : 1451 - 1467 .", "label": "", "metadata": {}, "score": "60.665886"}
{"text": "10.1093/jnci/88.24.1828 PubMed View Article .Stewart HJ , Everington D , McDonald CC , Dewar JA , Hawkins RA , Prescott RJ , George WD , The Scottish Cancer Trials Breast Group : Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer .", "label": "", "metadata": {}, "score": "60.697636"}
{"text": "The TCM group will receive YSJG granules , and the placebo group will receive placebo granules .Both groups will have a 12-week treatment period and a 12-week follow - up period .", "label": "", "metadata": {}, "score": "60.713623"}
{"text": "10.1200/JCO.2005.04.3034 PubMed View Article .a prospectively planned analysis of the TEAM trial .Br J Cancer 2013 , 109 : 2453 - 2461 .", "label": "", "metadata": {}, "score": "60.83634"}
{"text": "The P values for the test of interaction between goserelin and tamoxifen were 0.01 ( any event ) , 0.13 ( death from any cause ) , 0.016 ( BC recurrence ) , and 0.17 ( death from BC ) .", "label": "", "metadata": {}, "score": "60.838974"}
{"text": "Potential interventions for AIMSS usually include nonsteroidal anti - inflammatory drugs , analgesics , calcitriol agents , vitamin D , and exercise .Some patients even have to switch AIs or switch to tamoxifen because of severe musculoskeletal symptoms [ 11 , 12 ] .", "label": "", "metadata": {}, "score": "61.018127"}
{"text": "Switching of postmenopausal women with endocrine - responsive early breast cancer to anastrozole after 2 years ' adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial .", "label": "", "metadata": {}, "score": "61.079273"}
{"text": "Coombes RC , Hall E , Gibson LJ et al ( 2004 )A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer .", "label": "", "metadata": {}, "score": "61.124443"}
{"text": "The main questions were followed by subsections on why a particular choice was made .The webpage address was sent to contactable physicians whose emails were available in the oncology conference database .", "label": "", "metadata": {}, "score": "61.12767"}
{"text": "View Article .Lancet 2011 , 378 : 771 - 784 .PubMed View Article .: American society of clinical oncology / college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer .", "label": "", "metadata": {}, "score": "61.14295"}
{"text": "829 - 836 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. J. Bundred , I. D. Campbell , N. Davidson et al . , \" Effective inhibition of aromatase inhibitor - associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO - FAST study results , \" Cancer , vol .", "label": "", "metadata": {}, "score": "61.148933"}
{"text": "The important issue of tamoxifen for more than 5 years is discussed below ( ' Extended adjuvant endocrine therapy ' ) .Toxicities .Tamoxifen and the AIs ( see below ) are generally well tolerated with a low incidence of serious adverse effects ( SAEs ) .", "label": "", "metadata": {}, "score": "61.162827"}
{"text": "Although this study showed that there were no differences between TAM and ANA in premenopausal patients , the authors noted that the analysis was severely underpowered , since enough DFS events did not occur to note differences .", "label": "", "metadata": {}, "score": "61.215378"}
{"text": "While many patients report ' chemotherapy fog ' manifesting as a decrease in short - term memory during chemotherapy [ 84 ] , less is known about the potential effects of endocrine therapy on cognitive function [ 71 ] .", "label": "", "metadata": {}, "score": "61.375336"}
{"text": "Aromatase inhibitors for ovulation induction are orally administered , and are relatively inexpensive with minor side effects such as very infrequent headaches and leg cramps [ 8 ] .", "label": "", "metadata": {}, "score": "61.396893"}
{"text": "J Clin Oncol 28:3784 - 3796 CrossRef PubMed .Coates AS , Keshaviah A , Th\u00fcrlimann B et al ( 2007 )Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine - responsive early breast cancer : update of study BIG 1 - 98 .", "label": "", "metadata": {}, "score": "61.545086"}
{"text": "By indirect comparison , the magnitude of the benefit was similar to that seen with adjuvant chemotherapy or tamoxifen ( see below ) [ 5 , 6 ] .", "label": "", "metadata": {}, "score": "61.5586"}
{"text": "CYP2D6 genotyping and tamoxifen efficacy .Tamoxifen is metabolized by the cytochrome P450 2D6 ( CYP2D6 ) to 4-hydroxy tamoxifen and 4-hydroxy - N - desmethyl tamoxifen ( endoxifen ) , the latter metabolite being the more abundant and more potent in terms of ER - binding affinity and suppression of estradiol - stimulated cell proliferation [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "61.646645"}
{"text": "Crew KD , Greenlee H , Capodice J et al ( 2007 ) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early - stage breast cancer .", "label": "", "metadata": {}, "score": "61.656876"}
{"text": "Since there were 2 pair - wise comparisons being performed , a significance level of 2.5 % was used for the primary endpoint ( DFS ) analysis using a Bonferroni correction .", "label": "", "metadata": {}, "score": "61.90123"}
{"text": "Early Breast Cancer Trialists ' Collaborative Group : Polychemotherapy for early breast cancer : an overview of the randomised trials .Lancet 1998 , 352 : 930 - 942 .", "label": "", "metadata": {}, "score": "62.013115"}
{"text": "Through reviewing the literature and reported studies [ 20 , 23 , 26 ] , rheumatological questionnaires may be validated in the longitudinal assessment of joint symptoms , although the pathological processes are likely to be different .", "label": "", "metadata": {}, "score": "62.04441"}
{"text": "Investigators .JAMA 282:637 - 645 CrossRef PubMed .Delmas PD , Ensrud KE , Adachi JD et al ( 2002 )Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four - year results from a randomized clinical trial .", "label": "", "metadata": {}, "score": "62.053303"}
{"text": "Methods / design .Study design .This study is a multicenter , randomized , double - blind , placebo - controlled clinical trial with two parallel arms ( Figure 1 ) .", "label": "", "metadata": {}, "score": "62.08885"}
{"text": "Ettinger B , Black DM , Mitlak BH et al ( 1999 ) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial .", "label": "", "metadata": {}, "score": "62.306583"}
{"text": "There are , however , serious considerations associated with the use of AIs in the form of increased expense and adverse impact on quality of life with increased bone loss and joint pains [ 19 ] .", "label": "", "metadata": {}, "score": "62.31461"}
{"text": "ANA was associated with fewer thrombotic events and endometrial changes compared with TAM .The ZOL group had 904 patients , while the no ZOL group had 899 patients .", "label": "", "metadata": {}, "score": "62.36164"}
{"text": "Donnellan PP , Douglas SL , Cameron DA et al ( 2001 ) Aromatase inhibitors and arthralgia .J Clin Oncol 19:2767 PubMed .Rose C , Vtoraya O , Pluzanska A et al ( 2003 )", "label": "", "metadata": {}, "score": "62.374916"}
{"text": "Saarto T , Bloqvist C , Valimaki M et al ( 1997 )Clodronate improbe bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogen .", "label": "", "metadata": {}, "score": "62.53366"}
{"text": "De Boer R , Eidtmann H , Lluch A et al ( 2007 )The ZO - FAST trial : zoledronic acid effectively inhibits aromatase inhibitor associated bone loss in post - menopausal women with early breast cancer receiving adjuvant letrozole : 24 month BMD results .", "label": "", "metadata": {}, "score": "62.540504"}
{"text": "Hadji P , Body JJ , Aapro MS et al ( 2008 ) Practical guidance for the management of aromatase inhibitor- associated bone loss .Ann Oncol 19:1407 - 1416 CrossRef PubMed .", "label": "", "metadata": {}, "score": "62.593224"}
{"text": "Kennecke HF , Olivotto IA , Speers C , Norris B , Chia SK , Bryce C , Gelmon KA : Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen .", "label": "", "metadata": {}, "score": "62.658928"}
{"text": "10.1016/j.fertnstert.2008.07.006 .View Article .Malmusi S , La MA , Giulini S , Xella S , Tagliasacchi D , Marsella T , Volpe A : Comparison of a gonadotropin - releasing hormone ( GnRH ) antagonist and GnRH agonist flare - up regimen in poor responders undergoing ovarian stimulation .", "label": "", "metadata": {}, "score": "62.680275"}
{"text": "Objectives .We aim to determine the efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss ( AIBL ) in postmenopausal women with early breast cancer .", "label": "", "metadata": {}, "score": "62.718227"}
{"text": "Lipton A , Santen RJ : Proceedings : medical adrenalectomy using Aminoglutethimide and Dexamethasone in advanced breast cancer .Cancer 1974 , 33 : 503 - 512 .", "label": "", "metadata": {}, "score": "62.75047"}
{"text": "10.1093/jnci / djj357 .View Article .Casper RF , Mitwally MF : Review : aromatase inhibitors for ovulation induction .J Clin Endocrinol Metab .", "label": "", "metadata": {}, "score": "62.77609"}
{"text": "Data Sources , Search Strategy , and Study Selection .We systematically searched PubMed and Cochrane Collaboration library in a time period from January 1995 to June 2013 using the following terms : zoledronic acid , ibandronate , risedronate , aromatase inhibitor , BMD , and breast cancer .", "label": "", "metadata": {}, "score": "62.921143"}
{"text": "Eidtmann H , de Boer R , Bundred N ( 2010 )Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : 36-month results of the ZO - FAST Study .", "label": "", "metadata": {}, "score": "62.931587"}
{"text": "Aromatase inhibitors used in hormone responsive breast cancer , tend to lower BMD scores , and the patient with osteoporosis also suffers serious musculoskeletal ADRs from zoledronic acid therapy .", "label": "", "metadata": {}, "score": "62.95774"}
{"text": "6 , pp .1133 - 1137 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Liu , S. Zhao , W. Chen et al . , \" Bisphosphonates use and the risk of breast cancer : a meta - analysis of published literature , \" Clinical Breast Cancer , vol .", "label": "", "metadata": {}, "score": "62.998665"}
{"text": "J Natl Cancer Inst 2009 , 101 : 341 - 349 .10.1093/jnci / djn498 PubMed Central PubMed View Article .Dowsett M , Howell A : Breast cancer : aromatase inhibitors take on tamoxifen .", "label": "", "metadata": {}, "score": "63.004875"}
{"text": "Earl H , Gray R , Kerr D , Lee M : The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain : randomize into aTTom .", "label": "", "metadata": {}, "score": "63.019577"}
{"text": "Values for E 2 , P 4 and LH are shown in table 2 .However , the E 2 per preovulatory follicle was similar in all three groups on the day of hCG .", "label": "", "metadata": {}, "score": "63.039772"}
{"text": "Coleman RE , Banks LM , Girgis SI et al ( 2007 )Skeletal effects of exemestane on bone - mineral density , bone biomarkers , and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study ( IES ) : a randomised controlled study .", "label": "", "metadata": {}, "score": "63.097603"}
{"text": "10.1016/j.fertnstert.2007.02.062 .View Article PubMed .Badawy A , Shokeir T , Allam AF , Abdelhady H : Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility .", "label": "", "metadata": {}, "score": "63.168266"}
{"text": "View Article PubMed .Simon C , Cano F , Valbuena D , Remohi J , Pellicer A : Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients .", "label": "", "metadata": {}, "score": "63.209007"}
{"text": "There were no significant associations with serious adverse events .Author 's Conclusions .There were no significant differences seen in DFS , RFS , or OS between ANA and TAM in pre - menopausal women with Stage I or II breast cancer .", "label": "", "metadata": {}, "score": "63.271755"}
{"text": "PubMed View Article .J Clin Oncol 2007 , 25 : 486 - 492 .10.1200/JCO.2006.08.8617 PubMed View Article .Buzdar AU , on behalf of the ATAC Trialists ' Group : Clinical features of joint symptoms observed in the arimidex , tamoxifen , alone or in combination ( ATAC ) trial [ abstract 551].", "label": "", "metadata": {}, "score": "63.308075"}
{"text": "10.1016/S1472 - 6483(10)60611 - 6 .View Article .Goswami SK , Das T , Chattopadhyay R , Sawhney V , Kumar J , Chaudhury K , Chakravarty BN , Kabir SN : A randomized single - blind controlled trial of letrozole as a low - cost IVF protocol in women with poor ovarian response : a preliminary report .", "label": "", "metadata": {}, "score": "63.31254"}
{"text": "Delayed ZOL versus Immediate ZOL .The most common ADRs noted in the Z FAST , ZO FAST , and E - ZO FAST trials with zoledronic acid were bonepain , arthralgia , back pain , pain in extremities , and myalgia .", "label": "", "metadata": {}, "score": "63.323513"}
{"text": "10.1007/s10815 - 008 - 9209 - 2 .PubMed Central View Article PubMed .Topipat C , Choktanasiri W , Jultanmas R , Weerakiet S , Wongkularb A , Rojanasakul A : A comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on superovulation in Asian women with normal ovulatory cycles .", "label": "", "metadata": {}, "score": "63.356834"}
{"text": "Clinical / Scientific Implications .This prospective randomized trial provides relevant information regarding selection of hormonal treatment in pre - menopausal patients , and shows that the use of bisphosphonates , such as zoledronic acid , increases the effectiveness of current hormonal therapies .", "label": "", "metadata": {}, "score": "63.42888"}
{"text": "Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer .Interim analysis at four years by nolvadex adjuvant trial organisation Lancet 1983 , 1 : 257 - 261 .", "label": "", "metadata": {}, "score": "63.45284"}
{"text": "10.1093/jnci / djs139 PubMed View Article .Rae JM , Regan M , Leyland - Jones B , Hayes DF , Dowsett M : CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer .", "label": "", "metadata": {}, "score": "63.479103"}
{"text": "View Article PubMed .Badawy A , Abdel Aal I , Abulatta M : Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome : a prospective randomized trial .", "label": "", "metadata": {}, "score": "63.651478"}
{"text": "Sensitivity analysis was not performed due to small number of studies .All analyses were performed by using the software Comprehensive Meta - Analysis ( version 2.2.048 , Biostat , USA ) .", "label": "", "metadata": {}, "score": "63.6807"}
{"text": "Epub 2007 Jun 16 .Greenspan SL , Brufsky A , Lembersky BC ( 2008 )Risedronate prevents bone loss in breast cancer , survivors : a 2-year , randomized , double - blind , placebocontrolled clinical trial .", "label": "", "metadata": {}, "score": "63.81977"}
{"text": "Edwards SA , Chiarelli AM , Ritvo P et al ( 2011 )Satisfaction with initial screen and compliance with biennial breast screening at centers with and without nurses .", "label": "", "metadata": {}, "score": "63.877052"}
{"text": "10.1023/A:1008368300827 .View Article PubMed .Naftolin : Brain aromatization of androgens .J Reprod Med .PubMed .Robert F , Casper MFMM : Aromatase Inhibitors for Ovulation Induction .", "label": "", "metadata": {}, "score": "63.882816"}
{"text": "NP drafted the manuscript .XMW , GWY , and MWY supervised and coordinated the clinical trial .MWY participated in statistical design .QF , WRX , YZ , CM and NP are responsible for recruiting the participants .", "label": "", "metadata": {}, "score": "63.960114"}
{"text": "This benefit alone surpasses the combined gain obtained by all other interventions in the adjuvant setting [ 3 ] .Most noticeably , the hormonal therapy intervention benefits all the patients who are hormone positive , regardless of their tumor size and nodal status .", "label": "", "metadata": {}, "score": "63.992626"}
{"text": "Mitwally MF , Casper RF , Diamond MP : The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment .", "label": "", "metadata": {}, "score": "64.0188"}
{"text": "Statistical Analysis .Odds ratio with 95 % CI for dichotomous variables and standard mean difference with 95 % CI for continuous variables were used to assess the ADRs and BMD analysis .", "label": "", "metadata": {}, "score": "64.099594"}
{"text": "Most were medical oncologists in a tertiary care hospital .36.3 % preferred Anastrozole , 35.2 % Tamoxifen , and 22.2 % Letrozole as their first choice .", "label": "", "metadata": {}, "score": "64.1382"}
{"text": "Management of aromatase inhibitor - associated bone loss in postmenopausal women with breast cancer : practical guidance for prevention and treatment .Ann Oncol .[ Epub ahead of print ] .", "label": "", "metadata": {}, "score": "64.1632"}
{"text": "Extended adjuvant endocrine therapy with an AI ( post - menopausal ) or tamoxifen beyond an initial 5 years of tamoxifen further reduces the risk of relapse .", "label": "", "metadata": {}, "score": "64.17114"}
{"text": "PubMed View Article .Crew KD , Capodice JL , Greenlee H , Apollo A , Jacobson JS , Raptis G , Blozie K , Sierra A , Hershman DL : Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients .", "label": "", "metadata": {}, "score": "64.22246"}
{"text": "To reduce these effects , protective measures like reducing the dose , slowing the infusion rate , and prolonging the interval between infusions should be considered .", "label": "", "metadata": {}, "score": "64.297966"}
{"text": "Scand J Rheumatol 23:291 - 292 PubMed CrossRef .Warner E , Keshavjee al N , Shupak R et al ( 1997 )Rheumatic symptoms following adjuvant therapy for breast cancer .", "label": "", "metadata": {}, "score": "64.29869"}
{"text": "Tormey DC , Gray DC , Falkson HC , Eastern Cooperative Oncology Group : Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node - positive breast cancer .", "label": "", "metadata": {}, "score": "64.35504"}
{"text": "4882 PubMed CrossRef .Reid IR , Brown JP , Burckhardt P , Horowitz Z , Richardson P , Trechsel U , Widmer A , Devogelaer JP , Kaufman JM , Jaeger P , Body JJ , Meunier PJ ( 2002 ) Intravenous zoledronic acid in postmenopausal women with low bone mineral density .", "label": "", "metadata": {}, "score": "64.419525"}
{"text": "J Natl Compr Canc Netw 2009 , 7 : S1-S32 . quiz S33-S35 PubMed Central PubMed .Hadji P , Body JJ , Aapro MS , Brufsky A , Coleman RE , Guise T , Lipton A , Tubiana - Hulin M : Practical guidance for the management of aromatase inhibitor - associated bone loss .", "label": "", "metadata": {}, "score": "64.503586"}
{"text": "Markopoulos C , Tzoracoleftherakis E , Polychronis A et al ( 2010 )Management of anastrozole - induced bone loss in breast cancer patients with oral risedronate : results from the ARBI prospective clinical trial .", "label": "", "metadata": {}, "score": "64.551834"}
{"text": "10.1016/j.fertnstert.2008.03.020 .View Article PubMed .Baruah J , Roy KK , Rahman SM , Kumar S , Sharma JB , Karmakar D : Endometrial effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using spiral artery Doppler .", "label": "", "metadata": {}, "score": "64.57031"}
{"text": "Of note , the authors emphasized that the magnitude of the effects seen on DFS and OS in these analyses is likely underestimated because of some crossover after unblinding .", "label": "", "metadata": {}, "score": "64.57879"}
{"text": "New developments for treatment and prevention of bone metastases .Curr Opin Oncol 23:338 - 342 CrossRef PubMed .Singh S , Cuzick J , Edwards R et al .", "label": "", "metadata": {}, "score": "64.61462"}
{"text": "The steroidal AI Exemestane is prescribed in the least of AIs .Switch therapy has been found to be sufficiently practiced amongst our survey population where close to 64 % physicians actually do mention to switch the patients to Exemestane based on the data .", "label": "", "metadata": {}, "score": "64.63011"}
{"text": "Tamoxifen had been standard treatment for localized estrogen receptor - positive breast cancer ; however the ATAC trial has shown that clinical results are superior with an AI ( specifically anastrazole ) in postmenopausal women . \u00b7", "label": "", "metadata": {}, "score": "64.67662"}
{"text": "A study [ 21 ] suggested that the prevention of continuously decreasing BMD during endocrine treatment with aromatase inhibitors can be increased with the administration of bisphosphonates .", "label": "", "metadata": {}, "score": "64.78843"}
{"text": "Debilitating musculoskeletal pain and stiffness with letrozole and exemestane : associated tenosynovial changes on magnetic resonance imaging .Breast Cancer Res Treat 104:87 - 91 PubMed CrossRef .", "label": "", "metadata": {}, "score": "64.88791"}
{"text": "10.1016/S0936 - 6555(97)80067 - 2 View Article . : Long - term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor - positive breast cancer : ATLAS , a randomised trial .", "label": "", "metadata": {}, "score": "64.922516"}
{"text": "doi : 10 .1056/\u200bNEJMoa011807 PubMed CrossRef .Brufsky A , Harker WG , Beck JT , Carroll R , Tan - Chiu E , Seidler C , Hohneker J , Lacerna L , Petrone S , Perez EA ( 2007 ) Zoledronic acid inhibits adjuvant letrozole - induced bone loss in postmenopausal women with early breast cancer .", "label": "", "metadata": {}, "score": "64.95868"}
{"text": "Eastell R , Adams JE , Coleman RE et al ( 2008 )Effect of anastrozole on bone mineral density : 5-year results from the anastrozole , tamoxifen , alone or in combination trial 18233230 .", "label": "", "metadata": {}, "score": "64.97075"}
{"text": "840 - 849 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. M. Reid , J. Doughty , R. Eastell et al . , \" Guidance for the management of breast cancer treatment - induced bone loss : a consensus position statement from a UK Expert Group , \" Cancer Treatment Reviews , vol .", "label": "", "metadata": {}, "score": "65.01207"}
{"text": "There were individual differences in the frequency of followups and laboratory or radiological investigations requested by physicians .It seems that in general there is a lack of clear guidelines available to physicians on how to follow the patients after they are over with the active adjuvant treatments that involve chemotherapy and radiation therapy .", "label": "", "metadata": {}, "score": "65.01762"}
{"text": "Adjuvant endocrine therapy history : the first key steps .The first steps in the evolution of endocrine therapy are presented .First trials : oophorectomy .", "label": "", "metadata": {}, "score": "65.038864"}
{"text": "Aromatase inhibitors in cancer patients .The last five years letrozole has been introduced as an agent that could be used in cancer patients undergoing ovarian stimulation in order to preserve fertility prior chemotherapy , through embryo or oocyte cryopreservation [ 16 ] .", "label": "", "metadata": {}, "score": "65.08366"}
{"text": "Background .Aromatase inhibitors are drugs traditionally used for the treatment of hormone responsive advanced breast cancer [ 1 ] .The last decade several reports have supported these agents and potential drugs for ovulation induction .", "label": "", "metadata": {}, "score": "65.088104"}
{"text": "Also , the authors did not address for how long this therapy should optimally continue .Lastly , would a Tam \u00e0 AI switch be better than either treatment alone in pre - menopausal women ?", "label": "", "metadata": {}, "score": "65.1123"}
{"text": "Nolvadex ' Adjuvant trial organisation Br J Cancer 1988 , 57 : 608 - 611 .Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer .", "label": "", "metadata": {}, "score": "65.12993"}
{"text": "10.1016/S0140 - 6736(04)16981-X PubMed View Article .Early Breast Cancer Trialists ' Collaborative Group : Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer .", "label": "", "metadata": {}, "score": "65.2048"}
{"text": "GnRh agonist triggering in these patients may also have beneficial effects when combined with stimulation with letrozole , since in results in significantly lower post - triggering estradiol levels [ 19 ] .", "label": "", "metadata": {}, "score": "65.2282"}
{"text": "In the TEAM study , generally , gynecological symptoms and PE occurred more frequently in the sequential treatment group than in the exemestane - only group and the opposite was seen regarding the incidence of MSAEs ( 50 % versus 44 % ) , osteoporosis , and fractures .", "label": "", "metadata": {}, "score": "65.3026"}
{"text": "Clin Cancer Res 14:6336 - 6342 CrossRef PubMed .Eastell R , Van Poznak CH , Hannon RA et al ( 2007 )The SABRE study ( Study of Anastrozole with the Bisphosphonate RisedronatE ) : 12 month analysis .", "label": "", "metadata": {}, "score": "65.33505"}
{"text": "10.1186/bcr1991 .PubMed Central View Article .Oktay K , Hourvitz A , Sahin G , Oktem O , Safro B , Cil A , Bang H : Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy .", "label": "", "metadata": {}, "score": "65.36166"}
{"text": "At the time of trial unblinding , 1,579 women initially on placebo elected to receive letrozole and 804 women chose no further treatment .These results suggest that therapy given more than 7 years after diagnosis can change the chronic relapsing behavior of HR + BC .", "label": "", "metadata": {}, "score": "65.39122"}
{"text": "De Boer RH , Bundred N , Eidtmann H et al ( 2010 )The effect of zoledronic acid on aromatase inhibitor - associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole : the ZO - FAST study 5-year final follow - up .", "label": "", "metadata": {}, "score": "65.402794"}
{"text": "Int J Cancer 127:2893 - 2917 CrossRef PubMed .Goldhirsch A , Wood WC , Coates AS et al ( 2011 )Strategies for subtypes - dealing with the diversity of breast cancer : highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 .", "label": "", "metadata": {}, "score": "65.58426"}
{"text": "9472 , pp .1687 - 1717 , 2005 .View at Publisher \u00b7 View at Google Scholar .I. A. Jaiyesimi , A. U. Buzdar , D. A. Decker , and G. N. Hortobagyi , \" Use of tamoxifen for breast cancer : twenty - eight years later , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "65.66284"}
{"text": "author reply 1266 - 1268 10.1093/jnci / djs312 PubMed View Article .Stanton V Jr : Re : CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine - responsive breast cancer : the breast international group 1 - 98 trial .", "label": "", "metadata": {}, "score": "65.67631"}
{"text": "11 , pp .1022 - 1033 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Steves and J. M. Hootmant , \" Evidence - based medicine : what is it and how does it apply to athletic training ? \"", "label": "", "metadata": {}, "score": "65.739685"}
{"text": "10.1200/JCO.2010.34.4010 PubMed Central PubMed View Article .Shao J , Chang M , Chow SC : Statistical inference for cancer trials with treatment switching .", "label": "", "metadata": {}, "score": "65.77907"}
{"text": "Coombes RC , Kilburn LS , Snowdon CF et al ( 2007 ) Survival and safety of exemestane versus tamoxifen after 2 - 3 years ' tamoxifen treatment ( Intergroup Exemestane Study ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "65.7864"}
{"text": "Medical oncologists switched therapy more often than a clinical or radiation oncologists ( 0.002 ) .When the participants were asked about the number of investigation do they undertake before starting the treatment of the patients in early adjuvant breast cancer treatment for postmenopausal women , without a major known comorbidity , 73.6 % replied that they do some investigations .", "label": "", "metadata": {}, "score": "65.96513"}
{"text": "( aTTom ) trial randomly assigned 6,953 UK women in remission after 5 years of tamoxifen to 5 more years of tamoxifen or to stop ( Table 6 ) [ 114 ] .", "label": "", "metadata": {}, "score": "66.02908"}
{"text": "Ongoing trials such as the SOFT and TEXT trials are also comparing TAM with AIs in treatment of breast cancer in premenopausal women , and will hopefully help us better understand this question .", "label": "", "metadata": {}, "score": "66.037506"}
{"text": "10.1016/j.rbmo.2010.03.004 .PubMed Central View Article .Azim AA , Costantini - Ferrando M , Oktay K : Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer : a prospective controlled study .", "label": "", "metadata": {}, "score": "66.06158"}
{"text": "doi : 10 .1001/\u200bjama .2077 PubMed CrossRef .Harrington JT , Ste - Marie LG , Brandi ML , Civitelli R , Fardellone P , Grauer A , Barton I , Boonen S ( 2004 )", "label": "", "metadata": {}, "score": "66.0731"}
{"text": "Figure 8 : ( a ) Forest plot from meta - analysis of pain in extremity incidence of patients treated with immediate zoledronic acid versus delayed zoledronic acid .", "label": "", "metadata": {}, "score": "66.08331"}
{"text": "34 , supplement 1 , pp .S31-S42 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. B. Kimmel , \" Mechanism of action , pharmacokinetic and pharmacodynamic profile , and clinical applications of nitrogen - containing bisphosphonates , \" Journal of Dental Research , vol .", "label": "", "metadata": {}, "score": "66.11791"}
{"text": "Student 's t - tests and repeated - measure analyses of variance with a time - interaction term will be used to compare group differences .", "label": "", "metadata": {}, "score": "66.26256"}
{"text": "10.1016/j.fertnstert.2005.09.045 .View Article PubMed .Atay V , Cam C , Muhcu M , Cam M , Karateke A : Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation .", "label": "", "metadata": {}, "score": "66.33499"}
{"text": "Discussion .The results of this study will provide a new strategy to help relieve AIMSS .Trial registration .Keywords .Traditional Chinese medicine Aromatase inhibitor - associated musculoskeletal symptoms Breast cancer .", "label": "", "metadata": {}, "score": "66.33856"}
{"text": "Patient recruitment and counseling .We conducted a retrospective cohort study of 208 consecutive infertile patients who were recruited to participate .Briefly , patients underwent IUI between July of 2004 and January of 2007 at the Toronto Center For Assisted Reproductive Technology , Toronto , Canada .", "label": "", "metadata": {}, "score": "66.42238"}
{"text": "PubMed View Article . : Survival and safety of exemestane versus tamoxifen after 2 - 3 years ' tamoxifen treatment ( intergroup exemestane study ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "66.423004"}
{"text": "PubMed View Article .Khanduri S , Dodwell DJ : Aromatase inhibitors and musculoskeletal symptoms .Breast 2008 , 17 : 76 - 79 .PubMed View Article .", "label": "", "metadata": {}, "score": "66.46552"}
{"text": "c Must have completed 4 to 6 years of prior selective estrogen receptor modulators or aromatase inhibitors ( AIs ) , or a sequential combination of both .", "label": "", "metadata": {}, "score": "66.579056"}
{"text": "Hines SL , Mincey BA , Sloan JA ( 2009 )Phase III randomized , placebo - controlled , double - blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer .", "label": "", "metadata": {}, "score": "66.59544"}
{"text": "10.1093/jnci/94.19.1433 PubMed View Article .Early Breast Cancer Trialists ' Collaborative Group : Ovarian ablation in early breast cancer : overview of the randomised trials .", "label": "", "metadata": {}, "score": "66.74542"}
{"text": "We conducted a systematic review and meta - analysis to estimate the efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss and their safety in breast cancer in postmenopausal women .", "label": "", "metadata": {}, "score": "66.76747"}
{"text": "Breast Cancer Adjuvant Therapy with Zoledronic Acid .N Engl J Med 365(15):1396 - 1405 CrossRef PubMed .Lester JE , Dodwell D , Purohit OP et al ( 2008 )", "label": "", "metadata": {}, "score": "66.87817"}
{"text": "Brufsky A , Bundred N , Coleman R et al ( 2008 )Integrated analysis of zoledronic acid for prevention of aromatase inhibitor - associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole .", "label": "", "metadata": {}, "score": "66.896225"}
{"text": "The ESCEO working group recommends that all AI - treated women should be evaluated for fracture risk .Keywords .Aromatase inhibitors Bisphosphonates Bone loss Breast cancer Fracture risk .", "label": "", "metadata": {}, "score": "66.90068"}
{"text": "10.1002/pon.1379 PubMed View Article .Jenkins V , Shilling V , Fallowfield L , Howell A , Hutton S : Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ? a pilot study .", "label": "", "metadata": {}, "score": "66.92112"}
{"text": "Wolfe F , Michaud K , Strand V ( 2005 ) Expanding the definition of clinical differences : from minimally clinically important differences to really important differences .", "label": "", "metadata": {}, "score": "66.970375"}
{"text": "Figure 4 : ( a ) Forest plot from meta - analysis of the BMD change of patients on aromatase inhibitors treated with bisphosphonates ( ibandronate / risedronate ) compared with aromatase inhibitors alone in osteopenic patients .", "label": "", "metadata": {}, "score": "66.98082"}
{"text": "73.6 % used 5 years of adjuvant hormonal therapy , 6.6 % for 7 years , and 4.4 % for 10 years .61.5 % follow their patients 3 times monthly , and 73.2 % used laboratory and radiological assessment at each followup .", "label": "", "metadata": {}, "score": "67.00484"}
{"text": "10.1016/j.rbmo.2009.06.008 .View Article .Polyzos NP , Mauri D , Tzioras S : Letrozole in ovulation induction : time to make decisions .", "label": "", "metadata": {}, "score": "67.05318"}
{"text": "Demographic , clinical , and outcome variables will be described using means and standard deviations for continuous variables and percentages for categorical variables .The primary analysis will be to compare the mean pain scores from BPI - SF , the WOMAC , and the M - SACRAH and the mean joint stiffness and function scores from the WOMAC and the M - SACRAH between the TCM group and the placebo group .", "label": "", "metadata": {}, "score": "67.059074"}
{"text": "J. Ferlay , H. R. Shin , F. Bray , D. Forman , C. Mathers , and D. M. Parkin , \" Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 , \" International Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "67.09201"}
{"text": "Am J Surg 192:496 - 498 PubMed CrossRef .Thomas RJ , Marshall CJ , Williams M et al ( 2005 )Does switching to letrozole improve hot flushes , mood and quality of life in tamoxifen intolerant patients ?", "label": "", "metadata": {}, "score": "67.144516"}
{"text": "author reply 1266 - 1268 10.1093/jnci / djs304 PubMed View Article .Kelly CM , Pritchard KI : CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women : lessons learned .", "label": "", "metadata": {}, "score": "67.149956"}
{"text": "Median time to onset of symptoms was 1.6 months ( range 0.4 - 10 months ) .Clinical and laboratory evaluation of patients evaluated by rheumatology suggested that the majority developed either non - inflammatory musculoskeletal symptoms or inflammation localized to tenosynovial structures .", "label": "", "metadata": {}, "score": "67.17534"}
{"text": "This finding is likely artifactual since we suggest hCG administration to all women undergoing IUI so that timing of insemination can be optimized .The women undergoing natural cycle monitoring usually requested everything to be natural including no hCG trigger so the difference between the groups is unlikely to be related to the letrozole .", "label": "", "metadata": {}, "score": "67.2088"}
{"text": "10.1016/S1472 - 6483(10)60212-X. View Article .Garcia - Velasco JA , Quea G , Piro M , Mayoral M , Ruiz M , Toribio M , Requena A : Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function : a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "67.24739"}
{"text": "Block randomization was carried out in a 1:1 ratio according to the sequence generated with SAS ( Version 7.0 ; Channel - leadian pharmaceuticals R&D , Co. , Ltd ; No 19 , Xiao Ying Road , Chao Yang District , Beijing ) .", "label": "", "metadata": {}, "score": "67.261215"}
{"text": "Although 66 % of women originally on placebo crossed over to letrozole , a 32 % reduction in the hazard for a DFS event persisted for women originally randomly assigned to receive letrozole [ 102 ] .", "label": "", "metadata": {}, "score": "67.272964"}
{"text": "[ Epub ahead of print].Brufsky A , Bossermann L , Caradonna R et al ( 2009 ) Zoledronic acid effectively prevents aromatase inhibitor - associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole : the Z - FAST study 36 months follow - up results .", "label": "", "metadata": {}, "score": "67.30626"}
{"text": "The primary endpoint was DFS for both the comparisons of TAM vs. ANA and ZOL vs. no ZOL .Secondary endpoints included relapse - free survival ( RFS ) , overall survival ( OS ) , and safety .", "label": "", "metadata": {}, "score": "67.496506"}
{"text": "Sequential tamoxifen after an aromatase inhibitor .The other BIG 1 - 98 crossover arm also addressed the question of tamoxifen after 2 to 3 years of letrozole .", "label": "", "metadata": {}, "score": "67.526"}
{"text": "For serum Estradiol between group I and III .P value : 0.000 LH at day of HCG group I vs II .Follicular dynamics .", "label": "", "metadata": {}, "score": "67.52814"}
{"text": "Van Poznak C , Hannon RA , Mackey JR ( 2010 )Prevention of aromatase inhibitor - induced bone loss using risedronate : the SABRE trial .", "label": "", "metadata": {}, "score": "67.531784"}
{"text": "Inclusion Criteria .( i ) Randomised control trials published in English language , ( ii ) Studies that addressed the association between the third - generation bisphosphonates with aromatase inhibitor in breast cancer treatment , ( iii ) Studies that reported BMD . score after the treatment with bisphosphonate and aromatase inhibitor , ( iv ) Studies that addressed third - generation bisphosphonates ( zoledronic acid , ibandronate , and risedronate ) , ( v ) Postmenopausal women with early breast cancer .", "label": "", "metadata": {}, "score": "67.6292"}
{"text": "Adjuvant ovarian suppression .The real benefit may be greater because many of the women in these trials had unknown receptor status .The risk reduction for women younger than 40 years was not significantly different from those who were 40 to 49 .", "label": "", "metadata": {}, "score": "67.68952"}
{"text": "Smith IE , Fitzharris BM , McKinna JA , Fahmy DR , Nash AG , Neville AM , Gazet JC , Ford HT , Powles TJ : Aminoglutethimide in treatment of metastatic breast carcinoma .", "label": "", "metadata": {}, "score": "67.70706"}
{"text": "Chakravarty E , Genovese MC ( 2003 ) Rheumatic syndromes associated with malignancy .Curr Opin Rheumatol 15:35 - 43 PubMed CrossRef .Ohsako T , Inoue K , Nagamoto N et al ( 2006 )", "label": "", "metadata": {}, "score": "67.71669"}
{"text": "10.1016/j.fertnstert.2006.03.044 .View Article PubMed .Bayar U , Tanriverdi HA , Barut A , Ayoglu F , Ozcan O , Kaya E : Letrozole vs. clomiphene citrate in patients with ovulatory infertility .", "label": "", "metadata": {}, "score": "67.76039"}
{"text": "Conclusion .Third generation bisphosphonates has an effect on BMD of patients who are on treatment of AIs in breast cancer .Furthermore , the patients treated with immediate ZOL had a significantly high risk of musculoskeletal ADR 's than patients with delayed ZOL .", "label": "", "metadata": {}, "score": "67.79494"}
{"text": "With the propose of identifying what questions still need to be answered unequivocally from clinical trials that would set the standards from which this , the majority , of breast cancer patients would benefit the most .", "label": "", "metadata": {}, "score": "67.83786"}
{"text": "At a median follow - up of 30 months , a relative reduction in recurrence risk of 42 % occurred with letrozole [ 63 ] .", "label": "", "metadata": {}, "score": "67.94185"}
{"text": "This study is not yet a practice - changing trial , but it does open the door for studying yet another strategy for early breast cancer .", "label": "", "metadata": {}, "score": "67.99216"}
{"text": "Paterson AHG ( 2006 )The role of bisphosphonates in early breast cancer .Oncologist 11:S13-S19 CrossRef .Van den Wyngaert T , Huizing MT , Fossion E et al ( 2009 ) Bisphosphonates in oncology : rising stars or fallen heroes .", "label": "", "metadata": {}, "score": "68.04517"}
{"text": "The Royal Marsden NHS Foundation Trust , Breast Unit .The Institute of Cancer Research .References .Harvey JM , Clark GM , Osborne CK , Allred DC : Estrogen receptor status by immunohistochemistry is superior to the ligand - binding assay for predicting response to adjuvant endocrine therapy in breast cancer .", "label": "", "metadata": {}, "score": "68.0985"}
{"text": "Statistical analysis .Efficacy and safety analyses will be conducted according to the intention - to - treat principle .Missing values will be imputed by the last - observation - carried - forward method .", "label": "", "metadata": {}, "score": "68.16835"}
{"text": "The relative merits of adjuvant OvS , tamoxifen , or the two treatments combined are still controversial .A US Intergroup trial ( INT 0101 ) randomly assigned 1,503 pre - menopausal women pre - treated with chemotherapy to control arm ( no adjuvant endocrine therapy ) , 5 years of goserelin , or 5 years of goserelin plus tamoxifen [ 27 ] .", "label": "", "metadata": {}, "score": "68.18323"}
{"text": "In another trial of risedronate and anastrazole therapy ( ARBI trial ) [ 20 ] , it was found that there is a significant increase in BMD levels especially in high risk patients ( .", "label": "", "metadata": {}, "score": "68.264145"}
{"text": "N Engl J Med 353(26):2747 - 2757 .doi : 10 . 1056/\u200bNEJMoa052258CrossRef .Eastell R , Hannon RA , Cuzick J , Dowsett M , Clack G , Adams JE ( 2006 )", "label": "", "metadata": {}, "score": "68.31402"}
{"text": "Bundred NJ , Campbell ID , Davidson N et al ( 2008 ) Effective inhibition of aromatase inhibitor - associated bone loss by zoledronic acid in postmenopausal women receiving adjuvant letrozole : the ZO - FAST study results .", "label": "", "metadata": {}, "score": "68.34328"}
{"text": "Eligibility and exclusion criteria are presented in Table 1 .Pathologically confirmed stage I to III breast cancer with no recurrence and metastasis .Eastern Cooperative Oncology Group performance status 0 - 2 .", "label": "", "metadata": {}, "score": "68.47979"}
{"text": "Crew KD , Greenlee H , Capodice J , Raptis G , Brafman L , Fuentes D , Sierra A , Hershman DL : Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early - stage breast cancer .", "label": "", "metadata": {}, "score": "68.48972"}
{"text": "21 - 27 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . \"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "68.50706"}
{"text": "10.1007/s10549 - 013 - 2792 - 7 PubMed Central PubMed View Article .Collins B , Mackenzie J , Stewart A , Bielajew C , Verma S : Cognitive effects of chemotherapy in post - menopausal breast cancer patients 1 year after treatment .", "label": "", "metadata": {}, "score": "68.60629"}
{"text": "Muslimani AA , Spiro TP , Chaudhry AA , Taylor HC , Jaiyesimi I , Daw HA : Aromatase inhibitor - related musculoskeletal symptoms : is preventing osteoporosis the key to eliminating these symptoms ?", "label": "", "metadata": {}, "score": "68.802345"}
{"text": "Ensrud KE , Black DM , Palermo L et al ( 1997 )Treatment with alendronate prevents fractures in women at highest risk : results from the Fracture Intervention Trial .", "label": "", "metadata": {}, "score": "68.81653"}
{"text": "Gnant MF , Mlineritsch B , Luschin - Ebengreuth G et al ( 2007 ) Zoledronic acid prevents cancer treatment - induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone - responsive breast cancer : a report from the Austrian Breast and Colorectal Cancer Study Group .", "label": "", "metadata": {}, "score": "68.90157"}
{"text": "Reginster J , Minne HW , Sorensen OH et al ( 2000 ) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis .", "label": "", "metadata": {}, "score": "68.96966"}
{"text": "No significant differences in non - BC deaths or in the incidence of other cancers were found between groups .Endometrial cancer was diagnosed during treatment in 4 ( 0.2 % ) versus 11 ( 0.6 % ) patients on tamoxifen and letrozole , respectively .", "label": "", "metadata": {}, "score": "69.02707"}
{"text": "Chien AJ , Goss PE ( 2006 ) Aromatase inhibitors and bone health in women with breast cancer .J Clin Oncol 24:5305 - 5312 CrossRef PubMed .", "label": "", "metadata": {}, "score": "69.04303"}
{"text": "These have consistently shown benefit for the switch and indeed tended to have lower hazard ratios for DFS than direct upfront comparisons of ATAC and BIG 1 - 98 ( Tables 1 and 2 ) .", "label": "", "metadata": {}, "score": "69.04847"}
{"text": "Available randomized trials regarding the use of letrozole during the follicular phase in IVF / ICSI cycles .Poor responders .Only four randomized trials have been published through 2010 with a total of 235 patients with poor ovarian response randomized to receive letrozole combined with gonadotropins or gonadotropins alone as ovarian stimulation protocols in IVF / ICSI cycles ( Table 1 ) .", "label": "", "metadata": {}, "score": "69.165695"}
{"text": "Traditionally , treatment has been given for around 5 years , but many women remain at risk of relapse for 10 years or more .The AIs , and more recently tamoxifen , have been shown to reduce further the risk of late recurrence in women still in remission after 5 years of tamoxifen if given for a further 5 years .", "label": "", "metadata": {}, "score": "69.31082"}
{"text": "Furthemore , the administration of letrozole during the luteal phase offers a new insight for patients at high risk for OHSS .Despite the fact that the results are based solely on one randomized trial , if they are confirmed by future studies letrozole may have a role as a preventive measure for OHSS .", "label": "", "metadata": {}, "score": "69.333435"}
{"text": "Background .For over 40 years , the first - line therapy for ovulation induction ( OI ) has been clomiphene citrate ( CC ) [ 1 ] .", "label": "", "metadata": {}, "score": "69.365005"}
{"text": "SPSS software was used to analyze and prepare the descriptive data .Results .The survey was sent out to 522 physicians , a total of 182 physicians responded to the questionnaire , and the response percentage is 34.8 % .", "label": "", "metadata": {}, "score": "69.3881"}
{"text": "Holzer H , Casper R , Tulandi T : A new era in ovulation induction .Fertil Steril .10.1016/j.fertnstert.2005.05.078 .View Article PubMed . Noriega - Portella L , Noriega - Hoces L , Delgado A , Rubio J , Gonzales - Castaneda C , Gonzales GF : Effect of letrozole at 2.5 mg or 5.0 mg / day on ovarian stimulation with gonadotropins in women undergoing intrauterine insemination .", "label": "", "metadata": {}, "score": "69.46242"}
{"text": "Physicians vary over choices on the preferred agents of hormonal therapy in postmenopausal women in whom there are no significant comorbid .They also differ quite significantly among the duration , switching the therapy , frequency of followup , and necessary laboratory and radiological investigations in such setting .", "label": "", "metadata": {}, "score": "69.48513"}
{"text": "Figure 5 : ( a ) Forest plot from meta - analysis of arthralgia incidence of patients treated with immediate zoledronic acid versus delayed zoledronic acid .", "label": "", "metadata": {}, "score": "69.5329"}
{"text": "Th\u00fcrlimann B , Keshaviah A , Coates AS ( 2005 )A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer .Engl J Med 353:2747 - 2757 CrossRef .", "label": "", "metadata": {}, "score": "69.56737"}
{"text": "The optimal duration of extended adjuvant endocrine therapy remains unclear .An exploratory analysis conducted by Ingle and colleagues [ 104 ] suggested that the hazard ratio continues to fall for DFS and DDFS but not for OS out to 48 months , indicating that the benefit of letrozole increases with longer exposure .", "label": "", "metadata": {}, "score": "69.66081"}
{"text": "Cancer Treat Rev 34:S3-S18 CrossRef PubMed .Kanis JA , Johnell O , Oden A et al ( 2008 )FRAX \u2122 and the assessment of fracture probability in men and women from the UK .", "label": "", "metadata": {}, "score": "69.867325"}
{"text": "Perez EA ( 2007 ) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone - responsive early breast cancer .Ann Oncol 18:26 - 35 CrossRef .", "label": "", "metadata": {}, "score": "69.908295"}
{"text": "Conclusions .Adjuvant endocrine therapy significantly reduces the risk of recurrence and death in women with early HR + BC .In pre - menopausal women , tamoxifen and OvS are of similar benefit .", "label": "", "metadata": {}, "score": "69.981384"}
{"text": "Another limitation is the indeterminate diagnostic criteria of AIMSS .Musculoskeletal symptoms are reported according to different terms ( for example , arthralgia , joint symptoms , joint pain , and musculoskeletal symptoms ) in the literature .", "label": "", "metadata": {}, "score": "70.19763"}
{"text": "Sample size calculation .As there has been no similar TCM research on AIMSS to date , we calculated sample size according to another AIMSS study that used the same primary outcome measure ( BPI - SF ) [ 18 ] .", "label": "", "metadata": {}, "score": "70.29607"}
{"text": "Figure 9 : ( a ) Forest plot from meta - analysis of myalgia incidence of patients treated with immediate zoledronic acid versus delayed zoledronic acid .", "label": "", "metadata": {}, "score": "70.3401"}
{"text": "Fertil Steril .10.1016/j.fertnstert.2008.09.077 .View Article PubMed .Bedaiwy MA , Shokry M , Mousa N , Claessens A , Esfandiari N , Gotleib L , Casper R : Letrozole co - treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination .", "label": "", "metadata": {}, "score": "70.58688"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. J. Diel , R. Bergner , and K. A. Gr\u00f6tz , \" Adverse effects of bisphosphonates : current issues , \" Journal of Supportive Oncology , vol .", "label": "", "metadata": {}, "score": "70.64287"}
{"text": "PubMed .Zhang Q , Tang D , Zhao H : Immunological therapies can relieve aromatase inhibitor - related joint symptoms in breast cancer survivors .", "label": "", "metadata": {}, "score": "70.72302"}
{"text": "Friedman AJ , Juneau - Norcross M , Rein MS ( 1993 )Adverse effects of leuprolide acetate depot treatment .Fertil Steril 59:448 - 450 PubMed .", "label": "", "metadata": {}, "score": "70.758125"}
{"text": "Fertil Steril .10.1016/j.fertnstert.2006.04.026 .View Article PubMed .Serdar B : Ovulation induction in women with infertility : a new indication for aromatase inhibitors .", "label": "", "metadata": {}, "score": "70.78557"}
{"text": "In the risedronate and ibandronate trials , comparisons were made with placebo while the zoledronic acid trials were compared upfront versus delayed therapy .Table 1 gives the details of evidence - based approach in our study and Tables 2 and 3 give the characteristics of studies included and characteristics of patients included in our study , respectively .", "label": "", "metadata": {}, "score": "70.856995"}
{"text": "These clinical trials discussed more about metastatic stage of breast cancer that affected the bones [ 28 , 29 ] .Regarding efficacy both drugs appeared to have the same response .", "label": "", "metadata": {}, "score": "70.97026"}
{"text": "J Rheumatol 32:583 - 589 PubMed .Guy W ( 1976 )Clinical global impressions .In : ECDEU assessment manual for psychopharmacology .National Institute of Mental Health , Rockville .", "label": "", "metadata": {}, "score": "71.0026"}
{"text": "Second suggestion is that adverse effects in clinical trials and otherwise should be recorded and reported so that they can be evaluated in future trials and risk and benefit can be judged .", "label": "", "metadata": {}, "score": "71.04824"}
{"text": "It was also seen that few potentially life - threatening serious adverse events were noted with ANA compared to TAM .The addition of ZOL to endocrine therapy significantly prolonged DFS and RFS compared with endocrine therapy alone in pre - menopausal women with Stage I or II breast cancer .", "label": "", "metadata": {}, "score": "71.05788"}
{"text": "First trials .Tamoxifen and the Oxford overview .The first Oxford EBCTCG meta - analysis involved almost 30,000 women in 28 trials with either node - positive or node - negative BC who were randomly assigned to tamoxifen ( or not ) for about 5 years [ 12 ] .", "label": "", "metadata": {}, "score": "71.20859"}
{"text": "Boccardo F , Rubagotti A , Puntoni M et al ( 2005 )Switching to anastrozole versus continued tamoxifen treatment of early breast cancer : preliminary results of the Italian Tamoxifen Anastrozole trial .", "label": "", "metadata": {}, "score": "71.24069"}
{"text": "The physicians who still prefer to use Tamoxifen quote unique mechanism of action with possible intrinsic benefits and low cost as the reason behind the choice [ 4 ] .", "label": "", "metadata": {}, "score": "71.2561"}
{"text": "Osteoporos Int 20:239 - 244 CrossRef PubMed .Bischoff - Ferrari HA , Willett WC , Wong JB ( 2009 )Prevention of nonvertebral fractures with oral vitamin D and dose dependency : a meta - analysis of randomized controlled trials .", "label": "", "metadata": {}, "score": "71.34036"}
{"text": "Taking into account that the dose of gonadotropins and the cost is significantly lower whenever letrozole is used , such an approach may be the most realistic cost effective way to treat women with poor ovarian reserve .", "label": "", "metadata": {}, "score": "71.349014"}
{"text": "The findings of this study indicate that the third - generation bisphosphonates have positive effect on bone mineral density of patients who are suspected to or have suffered from bone loss , osteopenia , or osteoporosis due to the treatment of aromatase inhibitors in hormone responsive breast cancer .", "label": "", "metadata": {}, "score": "71.41251"}
{"text": "Current available evidence support that letrozole may have a promising role in stimulated IVF cycles , either when administered during the follicular phase for ovarian stimulation .", "label": "", "metadata": {}, "score": "71.646034"}
{"text": "The slight superiority of starting concurrently was , however , not significant , and these tamoxifen trials did not randomize timing .In all regimens , tamoxifen had a substantial effect .", "label": "", "metadata": {}, "score": "71.683334"}
{"text": "Systematic review can be applied to these literatures with some scientific strategies to provide in an explicit fashion a summary of all studies addressing a specific question , thereby allowing an account to be taken of the whole range of relevant findings on a particular topic .", "label": "", "metadata": {}, "score": "71.69714"}
{"text": "In addition in 2 trials in which pituitary downregulation in both treatment groups ( gonadotropins alone or gonadotropins co - administed with letrozole ) was performed with the use of a GnRH antagonist [ 4 , 11 ] , letrozole co - treated patients experienced comparable pregnancy rates .", "label": "", "metadata": {}, "score": "71.73192"}
{"text": "SABRE trial included in this study investigated the effects of adjuvant anastrazole with or without risedronate on BMD in postmenopausal women with hormone responsive early breast cancer and preexisting lower , moderate , and higher risk of fragility fracture .", "label": "", "metadata": {}, "score": "71.75751"}
{"text": "Nonetheless , letrozole co - treatment appeared to significantly augment endometrial thickness compared to FSH , an observation which may indeed explain both the increased implantation and ongoing pregnancy rates observed in these patients .", "label": "", "metadata": {}, "score": "71.846954"}
{"text": "There was also a statistically significant difference in RFS shown between the ZOL and no ZOL group .For OS , there was not a significant difference seen as the number of deaths was fortunately small .", "label": "", "metadata": {}, "score": "72.074295"}
{"text": "Tamoxifen was found , through series of studies , to render sufficient therapeutic benefits without significant toxicity to justify the title of being gold standard for antiestrogen treatment in breast cancer [ 11 ] .", "label": "", "metadata": {}, "score": "72.17615"}
{"text": "References .Howlader N , Noone AM , Krapcho M et al ( 2011 ) SEER Cancer Statistics Review , 1975 - 2008 , National Cancer Institute .", "label": "", "metadata": {}, "score": "72.368576"}
{"text": "One study reported a correlation between AIMSS and osteoporosis ( bone fractures ) [17 ] .In order to investigate the effects of YSJG on bone loss , bone mineral density ( BMD ) of the L2-L4 region of the spine and hip will be assessed before and after treatment ( at weeks 0 and 12 ) .", "label": "", "metadata": {}, "score": "72.37773"}
{"text": "The objective of this study was to compare letrozole - stimulated cycles to natural cycles in 208 patients undergoing intrauterine insemination ( IUI ) between July of 2004 and January of 2007 .", "label": "", "metadata": {}, "score": "72.41728"}
{"text": "477 CrossRef PubMed .Lazzeroni M , Gandini S , Puntoni M et al ( 2011 )The science behind vitamins and natural compounds for breast cancer prevention .", "label": "", "metadata": {}, "score": "72.46866"}
{"text": "Lancet 369:559 - 570 PubMed CrossRef .Burstein HJ ( 2007 )Aromatase inhibitor - associated arthralgia syndrome .Breast 16:223 - 234 PubMed CrossRef .", "label": "", "metadata": {}, "score": "72.490204"}
{"text": "Breast 20(Suppl 3):S36 - 41 .Garland CF , Comstock GW , Garland FC et al ( 1989 )Serum 25-hydroxyvitamin D and colon cancer : eight - year prospective study .", "label": "", "metadata": {}, "score": "72.56102"}
{"text": "Discussion .Endometrial sparing , increased folliculogenesis , and an increase in pregnancy rate were observed in our letrozole - treated patients as compared to naturally - cycling patients .", "label": "", "metadata": {}, "score": "72.57655"}
{"text": "Powles TJ , Hickish T , Kanis JA et al ( 1996 )Effect of tamoxifen on bone mineral density measured by dual - energy x - ray absorptiometry in healthy premenopausal and postmenopausal women .", "label": "", "metadata": {}, "score": "72.60654"}
{"text": "The newer third generation aromatase inhibitors have challenged this unparalleled status of tamoxifen in postmenopausal women , in whom cessation of ovarian function leaves only peripheral conversion of steroids as the source of production of estrogen and therefore making it an attractive target to block .", "label": "", "metadata": {}, "score": "72.61965"}
{"text": "However , tamoxifen was beneficial at ER concentrations as low as 10 fmol / mg of cytosol protein with improving efficacy at increasing ER measurements .", "label": "", "metadata": {}, "score": "72.847855"}
{"text": "Their use should also include the long agonist protocol for IVF , as this protocol is widely used .Off label inscription shall be re - evaluated from pharmaceutical industry and reproductive associations in order more appropriate randomized studies to be performed .", "label": "", "metadata": {}, "score": "72.87779"}
{"text": "Lancet Oncol 2008 , 9 : 1143 - 1148 .10.1016/S1470 - 2045(08)70259 - 6 PubMed View Article .Pritchard KI : Endocrine symptoms to predict risk of recurrence ?", "label": "", "metadata": {}, "score": "72.92015"}
{"text": "ATLAS , Adjuvant Tamoxifen : Longer Against Shorter ; aTToM , Adjuvant Tamoxifen - To Offer More ? ; BC , breast cancer ; CI , confidence interval ; EBC , early breast cancer ; RR , rate ratio ; T , tamoxifen .", "label": "", "metadata": {}, "score": "72.92159"}
{"text": "The benefit of OvA was sustained for up to 15 years , and an absolute difference in recurrence rate was 4.3 % .This questions whether relatively short LHRH analogue treatment used today for no more than 2 to 3 years is as effective as permanent ablation .", "label": "", "metadata": {}, "score": "72.98393"}
{"text": "10.1200/JCO.2009.25.6529 PubMed Central PubMed View Article .Jordan VC : Tamoxifen : toxicities and drug resistance during the treatment and prevention of breast cancer .", "label": "", "metadata": {}, "score": "73.08716"}
{"text": "Chen Z , Maricic M , Pettinger M et al ( 2005 ) Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer .", "label": "", "metadata": {}, "score": "73.10516"}
{"text": "Publisher main menu .Follow BioMed Central .Trials main menu .Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor - associated musculoskeletal symptoms : a study protocol for a multicenter , randomized , controlled clinical trial .", "label": "", "metadata": {}, "score": "73.16519"}
{"text": "PubMed View Article .Breast Cancer Res Treat 2008 , 111 : 365 - 372 .PubMed Central PubMed View Article .Niravath P : Aromatase inhibitor - induced arthralgia : a review .", "label": "", "metadata": {}, "score": "73.1995"}
{"text": "PubMed View Article .Galantino ML , Desai K , Greene L , Demichele A , Stricker CT , Mao JJ : Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor - associated arthralgias .", "label": "", "metadata": {}, "score": "73.2"}
{"text": "Patients with Normal Bone Mineral Density at Baseline .From the BMD analysis of LS BMD at 12 month , who had normal BMD at baseline , data from the trials were pooled together to get an overall summary data , with a statistically significant .", "label": "", "metadata": {}, "score": "73.20971"}
{"text": "In addition , our ovulation monitoring findings agree with a previous study showing multifollicular development and better pregnancy outcomes with the use of letrozole 5 mg / day [ 14 , 17 ] .", "label": "", "metadata": {}, "score": "73.22236"}
{"text": "The results for E 2 and P 4 levels were reported as picomoles per liter and nanomoles per liter , respectively , and LH and FSH levels were reported in international units per liter .", "label": "", "metadata": {}, "score": "73.22423"}
{"text": "A recent meta - analysis addressing the use of letrozole in assisted conception concluded that letrozole is as effective as other methods of ovulation induction [ 5 ] .", "label": "", "metadata": {}, "score": "73.30599"}
{"text": "Hadji P , Ziller M , Albert US et al ( 2010 ) Assessment of fracture risk in women with breast cancer using current vs emerging guidelines .", "label": "", "metadata": {}, "score": "73.44386"}
{"text": "Results of relatively small trials assessing tamoxifen treatment for more than 5 years were inconclusive until recently [ 109 - 112 ] .Most of this benefit seemed to accrue late , and there were only modest reductions in recurrence rates during the 5 extra years of tamoxifen and a more impressive carryover benefit during the 5 years of follow - up after completion of 10 years of tamoxifen ( Table 6 ) .", "label": "", "metadata": {}, "score": "73.53558"}
{"text": "Insignificant differences were also noticed based on designation , type , country , age , and years of practice .Discussion .The concept of breast cancer 's hormone sensitivity is more than a century old , when oophorectomies were shown to result in regression of advanced breast cancers [ 7 ] .", "label": "", "metadata": {}, "score": "73.59182"}
{"text": "We quantified the methodological qualities of studies using Jadad scores [ 14 ] .Funnel plots were used to test the publication bias and also the .", "label": "", "metadata": {}, "score": "73.6651"}
{"text": "Figure 7 : ( a ) Forest plot from meta - analysis of back pain incidence of patients treated with immediate zoledronic acid versus delayed zoledronic acid .", "label": "", "metadata": {}, "score": "73.67531"}
{"text": "10 , pp .1564 - 1571 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Agarwal and N. N. Rao , \" Bisphosphonates associated osteonecrosis of the jaws , \" Indian Journal of Dental Research , vol .", "label": "", "metadata": {}, "score": "73.705505"}
{"text": "The practice of evidence - based medicine involves a process of lifelong self - directed learning in which caring for patients creates the need for important information about clinical and other health care issues .", "label": "", "metadata": {}, "score": "73.728355"}
{"text": "Increasing numbers of specific AEs were also significantly associated with better survival outcomes .Similarly , a recent retrospective analysis of the BIG 1 - 98 trial suggests that the occurrence of arthralgia / myalgia / carpal tunnel symptoms at 3 and 12 months is associated with a significantly better DFS and BC - free interval irrespective of treatment ( letrozole or tamoxifen ) [ 83 ] .", "label": "", "metadata": {}, "score": "73.75948"}
{"text": "N Engl J Med 2003 , 349 : 1793 - 1802 .10.1056/NEJMoa032312 PubMed View Article .J Natl Cancer Inst 2007 , 99 : 1845 - 1853 .", "label": "", "metadata": {}, "score": "73.76304"}
{"text": "Authors ' Affiliations .Oncology Department , Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University .References .Early Breast Cancer Trialists ' Collaborative Group ( EBCTCG ) : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials .", "label": "", "metadata": {}, "score": "73.79823"}
{"text": "Tang SC ( 2010 ) Women and bone health : maximizing the benefits of aromatase inhibitor therapy .Oncology 79:13 - 26 CrossRef PubMed .Ghazi M , Roux C ( 2009 )", "label": "", "metadata": {}, "score": "73.89583"}
{"text": "J Natl Cancer Inst 2005 , 97 : 1262 - 1271 .10.1093/jnci / dji250 PubMed View Article .N Engl J Med 2009 , 361 : 766 - 776 .", "label": "", "metadata": {}, "score": "73.92056"}
{"text": "Therefore , the lower E 2 when using AIs may lead to an improvement of implantation [ 14 , 15 ] .There have been several studies comparing letrozole to CC .", "label": "", "metadata": {}, "score": "74.006676"}
{"text": "However , they reported that 26.6 % of the patients receiving oral ibandronate got upper gastrointestinal AEs .There were similar studies of meta - analysis on bisphosphonate use in breast cancer patients .", "label": "", "metadata": {}, "score": "74.09842"}
{"text": "10.1016/j.fertnstert.2008.04.042 .View Article .Maltaris T , Weigel M , Mueller A , Schmidt M , Seufert R , Fischl F , Koelbl H , Dittrich R : Cancer and fertility preservation : fertility preservation in breast cancer patients .", "label": "", "metadata": {}, "score": "74.163155"}
{"text": "The aim of this study was to compare cycle dynamics in letrozole - treated versus natural cycles in infertile patients undergoing intrauterine insemination ( IUI ) .", "label": "", "metadata": {}, "score": "74.24944"}
{"text": "Figure 6 : ( a ) Forest plot from meta - analysis of bone pain incidence of patients treated with immediate zoledronic acid versus delayed zoledronic acid .", "label": "", "metadata": {}, "score": "74.378815"}
{"text": "J Clin Oncol 25(5):486 - 491 .doi : 10 .1200/\u200bJCO .8617PubMed CrossRef .The Breast International Group ( BIG ) 1 - 98 Collaboratie Group ( 2005 )", "label": "", "metadata": {}, "score": "74.49545"}
{"text": "Shapiro CL , Manola J , Leboff M ( 2001 )Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early - stage breast cancer .", "label": "", "metadata": {}, "score": "74.55784"}
{"text": "Lonning P ( 2006 ) Bone safety of aromatase inhibitors versus tamoxifen .Int J Gynecol Cancer 16:518 - 520 CrossRef PubMed .Kanis JA , Melton LJ , Christiansen C 3rd et al ( 1994 )", "label": "", "metadata": {}, "score": "74.63439"}
{"text": "Best Pract Res Clin Rheumatol 23:805 - 811 CrossRef PubMed .L\u00f8nning PE , Geisler J , Krag LE ( 2005 ) Effects of exemestane administered for 2 years versus placebo on bone mineral density , bone biomarkers , and plasma lipids in patients with surgically resected early breast cancer .", "label": "", "metadata": {}, "score": "74.67265"}
{"text": "Therefore , due to the unsatisfactory response to current symptomatic treatments , many patients seek help from traditional Chinese medicine ( TCM ) .TCM , which has a unique advantage in alleviating symptoms and improving quality of life , has been widely applied in China for the treatment of cancer - related side effects , such as nausea , vomiting , fatigue , tidal fever , and pain [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "74.68643"}
{"text": "Second , after discontinuation of letrozole ( days 9 - 11 ) , serum LH returned to levels similar to the non - stimulated group reflecting the short half life of the letrozole .", "label": "", "metadata": {}, "score": "74.76619"}
{"text": "The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen .", "label": "", "metadata": {}, "score": "74.79252"}
{"text": "SOFT compares tamoxifen versus OvS plus tamoxifen versus OvS plus exemestane for 5 years .OvS can be achieved with gonadotropin - releasing hormone analog ( triptorelin ) for 5 years , oophorectomy or ovarian irradiation .", "label": "", "metadata": {}, "score": "74.8696"}
{"text": "However , given that in all of the trials letrozole has been administered in GnRH antagonist cycles , it is intriguing to test in the future how it may perform when used in GnRH agonist cycles .", "label": "", "metadata": {}, "score": "74.92718"}
{"text": "Compared to CC , letrozole has been associated with lower preovulatory estradiol ( E 2 ) levels [ 12 ] , as well as thicker endometrium and a trend towards higher pregnancy rates [ 13 ] .", "label": "", "metadata": {}, "score": "75.15344"}
{"text": "Breast Cancer Res Treat 125(3):869 - 878 .Holick MF , Binkley NC , Bischoff - Ferrari HA et al ( 2011 ) Evaluation , Treatment , and Prevention of Vitamin D Deficiency : an Endocrine Society Clinical Practice Guideline .", "label": "", "metadata": {}, "score": "75.21437"}
{"text": "Estradiol levels had higher variation in the second half of the follicular phase in both letrozole - treated groups compared to the control group .Estradiol per preovulatory follicle was similar in both letrozole cycles to that observed in the natural cycles .", "label": "", "metadata": {}, "score": "75.21833"}
{"text": "P value non - significant when comparing group I to either group II or III .Pregnancy rate .Three out of 63 natural cycles ( 4.8 % ) and 22 out of 185 letrozole cycles ( 12 % ) resulted in pregnancy ( table 5 ) .", "label": "", "metadata": {}, "score": "75.323074"}
{"text": "Categorical variables were compared using the \u03c7 2 and Fisher 's Exact Test .Statistical analysis was performed with SPSS ( Release 14.01 , SPSS Inc. , Chicago , IL ) .", "label": "", "metadata": {}, "score": "75.44125"}
{"text": "The lack of solid evidence in this field has been previously underlined [ 8 ] , and definitely prevent us from introducing these evidence in clinical practice .", "label": "", "metadata": {}, "score": "75.49666"}
{"text": "The BC recurrence rates were 16.7 % in the 10-year study group and 19.3 % in the 5-year study group .Similarly to the ATLAS trial , there was a time - dependent reduced risk of recurrence with 10 years of tamoxifen with RRs of 0.99 during years 5 to 6 , 0.84 during years 7 to 9 , and 0.75 subsequently .", "label": "", "metadata": {}, "score": "75.53899"}
{"text": "IUI was performed 36 - 40 hours after hCG administration if no endogenous LH surge occurred .If an endogenous LH surge was detected on the day of hCG administration , two IUIs were performed at 24 and 48 h. Pregnancy was diagnosed by quantitative \u03b2 - hCG assay two weeks after the insemination .", "label": "", "metadata": {}, "score": "75.64572"}
{"text": "Reproductive Sciences Division , Department of Obstetrics and Gynecology , University of Toronto .References .Casper RF : Aromatase inhibitors in ovarian stimulation .J Steroid Biochem Mol Biol .", "label": "", "metadata": {}, "score": "75.71535"}
{"text": "Publication Bias .Only in the case of bisphosphonate use in patients with normal BMD at baseline , publication bias was observed ( Figure 2(a ) ) .", "label": "", "metadata": {}, "score": "75.76868"}
{"text": "21 , 22 , 73 - 75 ] .Therefore , the simple adherence to implemented standard medical practice ( for example , bone health monitoring and vitamin D and calcium supplementation when appropriate ) should largely obviate the fracture risk associated with AI use .", "label": "", "metadata": {}, "score": "75.77204"}
{"text": "Results from bone sub - study of the International Breast Cancer Intervention Study ( IBIS - II ) .Breast Cancer Res Treat 2007 ; 106(Suppl 1 : S9 Abstr 28 ) .", "label": "", "metadata": {}, "score": "75.89877"}
{"text": "10.1016/j.fertnstert.2006.05.069 .View Article PubMed .Gorlitsky GAKN , Speroff L : Ovulation and pregnancy rates with clomiphene citrate .Obstet Gynecol .View Article PubMed .", "label": "", "metadata": {}, "score": "75.92769"}
{"text": "Holick MF ( 2007 )Vitamin D deficiency .N Engl J Med 357:266 - 281 CrossRef PubMed .Adami S , Giannini S , Bianchi G et al ( 2009 )", "label": "", "metadata": {}, "score": "75.957214"}
{"text": "Changes in the scores on these scales before and after intervention will be compared between the TCM group and the placebo group .Bone mineral density .", "label": "", "metadata": {}, "score": "76.13187"}
{"text": "The meta - analysis of these studies also showed the same results , that is , increase in BMD , when the bisphosphonate ( risedronate or ibandronate ) is included in the treatment regimen of the patients .", "label": "", "metadata": {}, "score": "76.1741"}
{"text": "Body mass index had a significant impact on the efficacy of anastrozole plus goserelin in these women [ 30 ] .The authors commented that incomplete suppression of estrogen production in peripheral body fat could be the cause of the reduced effect of anastrozole in the overweight and obese groups of patients .", "label": "", "metadata": {}, "score": "76.29291"}
{"text": "Outcome parameters .Hormonal outcome measures were E 2 , P 4 , LH and FSH .Non - hormonal outcomes were number and size of growing follicles , endometrial thickness , and pregnancy .", "label": "", "metadata": {}, "score": "76.37588"}
{"text": "Bone mineral density .BPI - SF : .Brief Pain Inventory - Short Form .ECOG : .Eastern Cooperative Oncology Group .FACT - B : .", "label": "", "metadata": {}, "score": "76.66499"}
{"text": "Donaldson MG , Palermo L , Schousboe JT et al ( 2009 ) FRAX and risk of vertebral fractures : the fracture intervention trial .J Bone Miner Res 24:1793 - 1799 CrossRef PubMed .", "label": "", "metadata": {}, "score": "76.69351"}
{"text": "The licensee has exclusive rights to distribute this article , in any medium , for 6 months following its publication .The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer :", "label": "", "metadata": {}, "score": "76.77826"}
{"text": "Although no treatments are specifically approved for AIBL , bisphosphonates are currently the intervention of choice for patients with low bone mineral density or evidence of rapid bone turnover , along with adequate calcium and vitamin D supplementation and a healthy lifestyle [ 9 ] .", "label": "", "metadata": {}, "score": "76.87766"}
{"text": ", Estrogen - dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole .Prevention with bisphosphonates , Bone .", "label": "", "metadata": {}, "score": "76.945"}
{"text": "Participants , investigators , statisticians , and all study staff are blinded .Outcome measures .Primary outcome measure .As pain is the most common complaint of AIMSS , we selected the Brief Pain Inventory - Short Form ( BPI - SF ) as the primary outcome measure to evaluate general pain .", "label": "", "metadata": {}, "score": "76.96074"}
{"text": "Nearly two - thirds of physicians ( 61.5 % ) followed their patients 3 - 6 monthly during the 1st year of followup while 21 % follow them every other month , 10 % every month , and 2 % follow their patients every 6 monthly .", "label": "", "metadata": {}, "score": "77.29842"}
{"text": "Tamoxifen exemestane adjuvant multinational .TEXT : .Tamoxifen and exemestane trial .TTDR : .Time to distant recurrence .TTR : .Time to recurrence .", "label": "", "metadata": {}, "score": "77.308716"}
{"text": "10.1200/JCO.2006.08.8054 PubMed View Article .J Clin Oncol 2012 , 30 : 722 - 728 .10.1200/JCO.2011.36.8993 PubMed View Article .Eur J Cancer 2013 , 49 : 1546 - 1554 .", "label": "", "metadata": {}, "score": "77.34207"}
{"text": "MH participated in the data collection .NM participated in the design of the study and performed the statistical analysis .LNB : participated in the data collection and helped to draft the manuscript .", "label": "", "metadata": {}, "score": "77.89337"}
{"text": "Statistical analysis .Data management was done using a preprepared Excel data spreadsheet .Outcome measures are expressed as mean \u00b1 standard deviation from the mean ( SD ) .", "label": "", "metadata": {}, "score": "77.96943"}
{"text": "Hillner B , Ingle J , Berenson J et al ( 2003 ) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in breast cancer .", "label": "", "metadata": {}, "score": "78.15253"}
{"text": "J Clin Oncol 11:768 - 770 PubMed .Michl I , Zielinski CC ( 1993 )More postchemotherapy rheumatism .J Clin Oncol 11:2051 - 2052 PubMed .", "label": "", "metadata": {}, "score": "78.16203"}
{"text": "PubMed View Article .N Engl J Med 2003 , 349 : 1793 - 1802 .PubMed View Article .J Natl Cancer Inst 2007 , 99 : 1845 - 1853 .", "label": "", "metadata": {}, "score": "78.2007"}
{"text": "Exclusion criteria .Patients with endocrine and any other diseases influencing bone metabolism ( for example , hyperthyroidism , hypothyroidism , diabetes , Cushing 's syndrome , chronic liver disease , nephropathy , myeloma , bone tumor , or bone metastasis ) .", "label": "", "metadata": {}, "score": "78.2702"}
{"text": "Joerger M , Th\u00fcrlimann B ( 2009 ) Update of the BIG 1 - 98 Trial : where do we stand ?Breast 18:S78-S82 CrossRef PubMed .", "label": "", "metadata": {}, "score": "78.38917"}
{"text": "We selected the WOMAC index to assess joint pain , stiffness , and functional status in the knees .The Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands ( M - SACRAH ) consists of three domains assessing pain , stiffness , and functional status in patients suffering from hand osteoarthritis and rheumatoid arthritis , answered on 100-mm visual analog scales .", "label": "", "metadata": {}, "score": "78.4138"}
{"text": "Bertoldo F , Pancheri S , Zenari S et al ( 2010 )Emerging drugs for the management of cancer treatment induced bone loss .Expert Opin Emerg Drugs 15:323 - 342 CrossRef PubMed .", "label": "", "metadata": {}, "score": "78.49138"}
{"text": "Conclusions Musculoskeletal side effects were common in AI - treated patients , resulting in therapy discontinuation in more than 10 % of patients .There are no identifiable pre - therapy indicators of risk , and the etiology remains elusive .", "label": "", "metadata": {}, "score": "78.607666"}
{"text": "M - SACRAH : .Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands .TCM : .Traditional Chinese medicine .", "label": "", "metadata": {}, "score": "78.89209"}
{"text": "10.1093/annonc / mdn164 PubMed View Article .J Clin Oncol 2003 , 21 : 4042 - 4057 .10.1200/JCO.2003.08.017 PubMed View Article .", "label": "", "metadata": {}, "score": "78.93436"}
{"text": "ER and progesterone receptor ( PgR ) status were strongly associated .The absolute recurrence reduction at 15 years seemed , if anything , greater in ER + PgR - poor than in ER + PgR + disease , perhaps because of the higher background risk of recurrence without treatment .", "label": "", "metadata": {}, "score": "79.023254"}
{"text": "Chen P , Hu P , Xie D et al ( 2010 ) Meta - analysis of vitamin D , calcium and the prevention of breast cancer .", "label": "", "metadata": {}, "score": "79.12747"}
{"text": "10.1200/JCO.2005.05.551 PubMed View Article .N Engl J Med 2009 , 360 : 679 - 691 .10.1056/NEJMoa0806285 PubMed View Article .", "label": "", "metadata": {}, "score": "79.15503"}
{"text": "Seventy - five percent of those were males , and 25 % were females .Most of the responding physicians were working either as private physicians or in teaching hospitals ( 40.7 % each ) .", "label": "", "metadata": {}, "score": "79.262856"}
{"text": "Materials and Methods .We searched electronic databases in a time period of 1995 January to 2013 June .Random effects meta - analytical models were used ; between study heterogeneity and publication bias was assessed .", "label": "", "metadata": {}, "score": "79.30095"}
{"text": "In our included studies of zoledronic acid , they have not mentioned osteonecrosis of jaw as their adverse event .When the number of studies incorporated is small , publication bias is to be considered .", "label": "", "metadata": {}, "score": "79.30266"}
{"text": "Extended adjuvant endocrine therapy .Women with HR + early BC are at continuous risk of relapse up to 15 years after diagnosis , despite being on adjuvant endocrine therapy for around 5 years [ 13 , 101 ] .", "label": "", "metadata": {}, "score": "79.316574"}
{"text": "Zoledronic acid which is a potent bisphosphonate has been shown to maintain or increase BMD in premenopausal women with early breast cancer or for those receiving adjuvant hormone therapies as well as healthy postmenopausal women [ 16 , 17 , 22 ] .", "label": "", "metadata": {}, "score": "79.69084"}
{"text": "In preclinical and early clinical studies , zoledronic acid ( ZOL ) is a very potent bisphosphanate , and has been shown to have a direct anti - tumor effect and anti - metastatic effect by inhibiting tumor growth , stimulating immune response and inhibiting angiogenesis .", "label": "", "metadata": {}, "score": "79.90236"}
{"text": "These carryover benefits contribute substantially to the cumulative benefits of treatment , particularly because toxic effects occur mostly during the active treatment period .Reassuringly , no increase was noted in stroke incidence , and a decrease in incidence of ischemic heart disease was noted ( 0.76 ) .", "label": "", "metadata": {}, "score": "79.92061"}
{"text": "Data Extraction .Data extraction performed independently by two observers ( APP and SS ) , with disagreements resolved by the third observer ( AV ) .", "label": "", "metadata": {}, "score": "79.92574"}
{"text": "Most breast cancers ( 60 % ) express oestrogen receptor ( ER ) or progesterone receptor ( PR ) and are responsive to estrogens for growth and proliferation .", "label": "", "metadata": {}, "score": "79.937546"}
{"text": "Ibandronate is the only one new third - generation bisphosphonates that has developed in both intravenous and oral formulations for the management of bone disorders [ 26 ] .", "label": "", "metadata": {}, "score": "79.96604"}
{"text": "Regarding compliance , Cuzick and colleagues [ 80 ] , in contrast with other investigators , noted better treatment adherence in patients experiencing vasomotor symptoms and joint symptoms .", "label": "", "metadata": {}, "score": "80.11786"}
{"text": "Denosumab is an antireceptor activator of nuclear factor- ( NF- ) kappa ligand ( RANK ) ligand human monoclonal antibody , which is also a treatment option for bone reduction in metastatic cancers .", "label": "", "metadata": {}, "score": "80.18448"}
{"text": "Eur J Cancer 2006 , 42 : 2968 - 2975 .10.1016/j.ejca.2006.07.005 PubMed View Article .San Antonio , TX : Paper presented at : 31st Annual San Antonio Breast Cancer Symposium ; 2008:1128 .", "label": "", "metadata": {}, "score": "80.28813"}
{"text": "View Article .Casper RF : Letrozole versus clomiphene citrate : which is better for ovulation induction ?Fertil Steril .10.1016/j.fertnstert.2007.03.094 .View Article PubMed .", "label": "", "metadata": {}, "score": "80.46393"}
{"text": "22 , pp .3758 - 3767 , 2000 .View at Google Scholar \u00b7 View at Scopus .26 , no .30 , pp .", "label": "", "metadata": {}, "score": "80.595505"}
{"text": "However , letrozole may serve as an alternative for patients with poor ovarian response .A very important observation from the available data , is that a treatment protocol with GnRH antagonists , letrozole and gonadotrophins , hints a danger for compromising clinical pregnancy rates compared to treatment with gonadotropins in a microdose GnRH agonist protocol .", "label": "", "metadata": {}, "score": "80.609505"}
{"text": "Calcif Tissue Int 74:129 - 135 .doi : 10 .1007/\u200bs00223 - 003 - 0042 - 4 PubMed CrossRef .About this Article .Title .", "label": "", "metadata": {}, "score": "80.83708"}
{"text": "Eighty - four participants will be recruited from three centers : Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University , Beijing Cancer Hospital , and Guang ' Anmen Hospital affiliated with China Academy of Chinese Medical Sciences .", "label": "", "metadata": {}, "score": "81.065865"}
{"text": "In hormone receptor - positive breast cancers , growth of the tumor is stimulated by estrogens .Decreasing the production of estrogens therefore leads to suppression of recurrence , and drugs such as tamoxifen and aromatase inhibitors are useful for this purpose .", "label": "", "metadata": {}, "score": "81.13053"}
{"text": "15 , pp .2270 - 2278 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Beatson , \" On the treatment of inoperable cases of carcinoma of the mamma : suggestions for a new method of treatment , with illustrative cases , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "81.14811"}
{"text": "In conclusion , in ER + disease , continuing tamoxifen to year 10 rather than just to year 5 produces further reductions in recurrence , from year 7 onward , and BC mortality after year 10 .", "label": "", "metadata": {}, "score": "81.16104"}
{"text": "PubMed View Article .N Engl J Med 2005 , 353 : 2747 - 2757 .PubMed View Article .Cancer Res 2009 , 69 : 67s .", "label": "", "metadata": {}, "score": "81.22449"}
{"text": "author reply 1266 - 1268 10.1093/jnci / djs305 PubMed View Article .J Natl Cancer Inst 2012 , 104 : 441 - 451 .", "label": "", "metadata": {}, "score": "81.318375"}
{"text": "Denosumab can be an alternative for BPs therapy only if the patient has renal insufficiency .If we compare the safety profiles of these two drugs , osteonecrosis of jaw was common in both cases and also acute phase reactions and flu - like symptoms are less common in BPs IV therapy [ 30 ] .", "label": "", "metadata": {}, "score": "81.67932"}
{"text": "11 , pp .1081 - 1092 , 2004 .View at Publisher \u00b7 View at Google Scholar .30 , no . 7 , pp .", "label": "", "metadata": {}, "score": "81.69285"}
{"text": "There is now in addition a data to support the switch strategy , in which one agent is alternated with the other , to have actually more beneficial effects than traditionally used continuous single agent for five years [ 5 ] .", "label": "", "metadata": {}, "score": "81.732185"}
{"text": "Szabo KA , Webber CE , Adachi JD et al ( 2011 )Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients : a Peripheral Quantitative Computed Tomography ( pQCT ) study .", "label": "", "metadata": {}, "score": "81.9028"}
{"text": "Pansini F , Albertazzi P , Bonaccorsi G et al ( 1994 )The menopausal transition : a dynamic approach to the pathogenesis of neurovegetative complaints .", "label": "", "metadata": {}, "score": "81.94371"}
{"text": "Tubal patency was confirmed by sonohysterography with contrast , hysterosalpingography , and or pelvic laparoscopy .Mild male factor infertility was diagnosed according to the World Health Organization ( WHO ) criteria for normal semen [ 16 ] .", "label": "", "metadata": {}, "score": "82.02454"}
{"text": "Table 6 summarizes the results of some trials using letrozole as an ovulation inducing agent in different clinical scenaria with different results and conclusions .Letrozole has better ovulation and PR in comparison to CC in patients with PCOS .", "label": "", "metadata": {}, "score": "82.07025"}
{"text": "Management of cancer treatment - induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian bone club .Osteoporos Int 18:1439 - 1450 CrossRef PubMed .", "label": "", "metadata": {}, "score": "82.394"}
{"text": "Management of cancer treatment - induced bone loss in early breast and prostate cancer - a consensus paper of the Belgian Bone Club .Osteoporos Int 18:1439 - 1450 CrossRef PubMed .", "label": "", "metadata": {}, "score": "82.394"}
{"text": "Normoresponders .Only one randomized trial has been conducted up - to - date that evaluated the addition of letrozole in patients with normal ovarian response undergoing IVF or ICSI [ 9 ] .", "label": "", "metadata": {}, "score": "82.431"}
{"text": "J Clin Oncol 2001 , 19 : 3808 - 3816 .PubMed .J Clin Oncol 2005 , 23 : 5108 - 5116 .10.1200/JCO.2005.04.005 PubMed View Article .", "label": "", "metadata": {}, "score": "82.546616"}
{"text": "10.1016/S1470 - 2045(08)70291 - 2 PubMed View Article .J Clin Oncol 2013 , 31 : 2257 - 2264 .10.1200/JCO.2012.45.3068 PubMed View Article .", "label": "", "metadata": {}, "score": "82.618225"}
{"text": "PubMed View Article .Burstein HJ : Aromatase inhibitor - associated arthralgia syndrome .Breast 2007 , 16 : 223 - 234 .PubMed View Article .", "label": "", "metadata": {}, "score": "82.65788"}
{"text": "650 CrossRef PubMed .Kanis JA , McCloskey EV , Powles T et al ( 1999 )A high incidence of vertebral fracture in women with breast cancer .", "label": "", "metadata": {}, "score": "82.84468"}
{"text": "10.1111/j.0006 - 341X.2000.00779.x PubMed View Article .J Clin Oncol 2011 , 29 : 1117 - 1124 .10.1200/JCO.2010.31.6455 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "82.97992"}
{"text": "There are several limitations to our study .One limitation is the absence of specific measures for AIMSS .AIMSS is a set of symptoms involving the bone , muscles and joints .", "label": "", "metadata": {}, "score": "83.04189"}
{"text": "Ovarian suppression is of similar efficacy but currently there is no strong evidence for adding this to tamoxifen and the additional morbidity can be considerable .", "label": "", "metadata": {}, "score": "83.11214"}
{"text": "Suggestion from the meta - analysis is that measuring the bone mineral density at intermittent intervals of time throughout the therapeutic regimen should be recorded and reported and bisphosphonates therapy should be started accordingly .", "label": "", "metadata": {}, "score": "83.67885"}
{"text": "27 , pp .3715 - 3716 , 2011 .View at Publisher \u00b7 View at Google Scholar .20 , no . 8 , pp .", "label": "", "metadata": {}, "score": "83.73425"}
{"text": "Bruce B , Fries JF ( 2003 )The Stanford Health Assessment Questionnaire : a review of its history , issues , progress , and documentation .", "label": "", "metadata": {}, "score": "83.8297"}
{"text": "10.1016/S0140 - 6736(12)61963 - 1 PubMed Central PubMed View Article .Chicago , IL : Paper presented at : 49th Annual Meeting of the American Society of Clinical Oncology ; 2013 .", "label": "", "metadata": {}, "score": "83.99014"}
{"text": "doi : 10 .1002/\u200bcncr . 11745CrossRef .N Engl J Med 349(19):1793 - 1802 .doi : 10 .1056/\u200bNEJMoa032312 PubMed CrossRef .N Engl J Med 350(11):1081 - 1092 .", "label": "", "metadata": {}, "score": "84.10465"}
{"text": "10.1016/S1470 - 2045(11)70122-X PubMed View Article .J Clin Oncol 2011 , 29 : 2653 - 2659 .10.1200/JCO.2010.33.2585 PubMed View Article .", "label": "", "metadata": {}, "score": "84.11459"}
{"text": "Breast Cancer Res Treat 2006 , 99 : 295 - 300 .10.1007/s10549 - 006 - 9207-y PubMed View Article .J Clin Oncol 2008 , 26 : 1948 - 1955 .", "label": "", "metadata": {}, "score": "84.23091"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Department of Obstetrics and Gynecology , University Hospitals Case Medical Center , Case Western Reserve University School of Medicine .", "label": "", "metadata": {}, "score": "84.26163"}
{"text": "Project overview .1 BPI - SF : Brief Pain Inventory - Short Form ( Chinese version ) .2 WOMAC 3.1 Index : Western Ontario and McMaster Universities Osteoarthritis Index ( Chinese version ) .", "label": "", "metadata": {}, "score": "84.723236"}
{"text": "Osteoporos Int 21:1121 - 1132 CrossRef PubMed .Peterlik M , Grant WB , Cross HS et al ( 2007 ) Calcium , vitamin D and cancer .", "label": "", "metadata": {}, "score": "84.987854"}
{"text": "In summary , letrozole results in some minor changes in follicular , hormonal and endometrial dynamics compared to natural cycles .Increased folliculogenesis and pregnancy rates were observed in the letrozole - treated groups compared to the natural group .", "label": "", "metadata": {}, "score": "85.07451"}
{"text": "It was also interesting to see that the effects of ZOL were not limited to bone .It is a well - tolerated and safe drug which appears to be promising in breast cancer .", "label": "", "metadata": {}, "score": "85.45028"}
{"text": "26 , no . 7 , pp .1051 - 1057 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "85.577545"}
{"text": "10.1200/JCO.2007.11.0726 PubMed View Article .Ann Oncol 2009 , 20 : 1203 - 1209 .10.1093/annonc / mdn762 PubMed View Article .", "label": "", "metadata": {}, "score": "85.68952"}
{"text": "The uterine cancer risk was strongly correlated with age , with little absolute risk for entry age of less than 45 years or 45 to 54 years .", "label": "", "metadata": {}, "score": "86.20291"}
{"text": "10.1200/JCO.2008.21.3553 PubMed View Article .J Clin Oncol 2008 , 26 : 5569 - 5575 .10.1200/JCO.2008.17.0829 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "86.35487"}
{"text": "So , the findings should be carefully understood .From the above analysis , it may be concluded that bisphosphonate has a positive role in the bone health of postmenopausal breast cancer patients on aromatase inhibitors and may be added to standard adjuvant therapy to improve the prognosis in postmenopausal patients .", "label": "", "metadata": {}, "score": "86.36194"}
{"text": "However , we believe the results are of interest since there are few studies comparing natural cycles to letrozole - stimulated cycles .The main distinguishing features of letrozole as an ovulation inducing agent is its endometrial sparing effect and the early cycle multi - follicular development that may have translated into a better pregnancy rate in the present study .", "label": "", "metadata": {}, "score": "86.6249"}
{"text": "In : Abstracts from the 29th Annual San Antonio Breast Cancer Symposium , San Antonio , 14 - 17 Dec 2006 .About this Article .", "label": "", "metadata": {}, "score": "87.038506"}
{"text": "PubMed .J Clin Oncol 2003 , 21 : 984 - 990 .10.1200/JCO.2003.01.138 PubMed View Article .Oncologist 2008 , 13 : 829 - 837 .", "label": "", "metadata": {}, "score": "87.04141"}
{"text": "Heterogeneity .Heterogeneity can be judged graphically , by looking at the forest plot , and can be measured statistically .From Table 5 , all the .", "label": "", "metadata": {}, "score": "87.042435"}
{"text": "PubMed Central PubMed View Article .Lin C , Lin X , Yang J : An observation on combined use of chemotherapy and traditional Chinese medicine to relieve cancer pain .", "label": "", "metadata": {}, "score": "87.298935"}
{"text": "View Article .Lancet 2005 , 365 : 60 - 62 .PubMed View Article .N Engl J Med 2005 , 353 : 2747 - 2757 .", "label": "", "metadata": {}, "score": "87.35261"}
{"text": "Tuohimaa P , Tenkanen L , Ahonen M et al ( 2004 )Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk : a longitudinal , nested case - control study in the Nordic countries .", "label": "", "metadata": {}, "score": "87.52981"}
{"text": "Crit Rev Oncol Hematol 2013 , 86 : 23 - 32 .10.1016/j.critrevonc.2012.09.013 PubMed View Article .J Natl Cancer Inst 1996 , 88 : 1529 - 1542 .", "label": "", "metadata": {}, "score": "87.86583"}
{"text": "Prentice AM ( 2008 )Vitamin D deficiency : a global perspective .Nutr Rev 66:S153-S164 CrossRef PubMed .Mithal A , Wahl DA , Bonjour JP et al ( 2009 )", "label": "", "metadata": {}, "score": "88.03251"}
{"text": "Because they do not deplete estrogen receptors like CC , normal central feedback mechanisms remain intact [ 10 ] .As the dominant follicle grows and estrogen levels rise , normal negative feedback occurs centrally resulting in suppression of FSH and atresia of the smaller growing follicles .", "label": "", "metadata": {}, "score": "88.239075"}
{"text": "PubMed .Zhou D : Oncology of Traditional Chinese Medicine .Beijing : China Press of Traditional Chinese Medicine ; 2011 .Sun G , Tong Y , Chen W : Basic Theory of Traditional Chinese Medicine .", "label": "", "metadata": {}, "score": "88.35782"}
{"text": "J Bone Miner Res 21(8):1215 - 1223 .doi : 10 .1359/\u200bjbmr . 060508PubMed CrossRef .J Clin Oncol 24(22):3629 - 3635 .doi : 10 .", "label": "", "metadata": {}, "score": "88.60656"}
{"text": "National Cooperative Reproductive Medicine Network .N Engl J Med .10.1056/NEJM199901213400302 .View Article PubMed .Hum Reprod Update .10.1093/humupd / dmn033 .", "label": "", "metadata": {}, "score": "88.778465"}
{"text": "Other identified causes of infertility included endometriosis , and polycystic ovarian syndrome .The most frequent cause of cycle cancellation differed among the patient groups .", "label": "", "metadata": {}, "score": "88.85991"}
{"text": "Contraindications to calcium agents and vitamin D. .Diagnosed with primary osteoarticular diseases .Presence of other primary tumors and severe heart , liver , kidney , and hematopoietic system diseases .", "label": "", "metadata": {}, "score": "89.15288"}
{"text": "Breast cancer is the leading cause of premature morbidity and mortality worldwide for women .More than 800,000 women are diagnosed with breast cancer approximately , and an estimated 65 % to 75 % of the patients with advanced metastases will develop bone metastases during the course of their disease .", "label": "", "metadata": {}, "score": "89.47973"}
{"text": "95 , no . 1 - 5 , pp .75 - 81 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "89.48111"}
{"text": "HMG : . human menopausal gonadotropin .FSH : . follicular stimulating hormone .GnRH : . gnonadotropin releasing hormone .LH : . luteinising hormone .", "label": "", "metadata": {}, "score": "89.627335"}
{"text": "Reviewer : Arpi Thukral , MD Abramson Cancer Center of the University of Pennsylvania Last Modified : June 1 , 2008 .Presenter : M. Gnant Presenter 's Affiliation : Medical University of Vienna Type of Session : Scientific .", "label": "", "metadata": {}, "score": "90.01334"}
{"text": "d Intermittent : 48 months over 5 years : 4 \u00d7 9 months ( 9 months followed by 3-month treatment - free interval in years 1 to 4 , at least 36 months ) plus 1 \u00d7 12 months in years 5 at least 48 months .", "label": "", "metadata": {}, "score": "90.17303"}
{"text": "20 , no . 9 , pp .1489 - 1498 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "90.56206"}
{"text": "This rise might be due to the release of the anterior pituitary from the negative feedback of E 2 .Three important observations deserve mentioning .", "label": "", "metadata": {}, "score": "90.68182"}
{"text": "Competing interests .The authors declare that they have no competing interests .Authors ' contributions .MAB collected and analyzed the data and drafted the manuscript .", "label": "", "metadata": {}, "score": "90.74377"}
{"text": "The primary endpoint was the mean percent change in lumbar spine ( LS ) BMD at 1 year .About 558 women enrolled ; 395 provided 1 year BMD data .", "label": "", "metadata": {}, "score": "90.79811"}
{"text": "2011Sep 15 .[ Epub ahead of print ] .Prieto - Alhambra D , Javaid MK , Servitja S et al ( 2011Feb )", "label": "", "metadata": {}, "score": "90.98074"}
{"text": "Hormone therapy , which essentially deprives the tumor cells of hormone , relies on the fact that the tumor cells from the breast retain the property of thriving in the presence of female sex hormones , and dispossession of which results in inhibition of cancer cell regrowth .", "label": "", "metadata": {}, "score": "91.01836"}
{"text": "Ltd ( No 5 , Niu Hui Street , Shun Yi District , Beijing ) according to the standards of Good Manufactoring Practice .Patients will be instructed to dissolve a sachet of granules ( 12.4 g ) in 200 mL hot water and to take the solution orally twice a day for 12 weeks .", "label": "", "metadata": {}, "score": "91.07292"}
{"text": "Special thanks to all participants in this study .Competing interests .The authors declare that they have no competing interests .Authors ' contributions .", "label": "", "metadata": {}, "score": "91.14907"}
{"text": "J Clin Oncol 2008 , 26 : 1059 - 1065 .10.1200/JCO.2007.12.9437 PubMed View Article .Lancet Oncol 2008 , 9 : 23 - 28 .", "label": "", "metadata": {}, "score": "91.265976"}
{"text": "Ann Oncol 2011 , 22 : 2201 - 2207 .10.1093/annonc / mdq738 PubMed Central PubMed View Article .Cancer Res 2012 , 72 : S1 - 1 .", "label": "", "metadata": {}, "score": "91.56018"}
{"text": "Patients in the upfront arm were slightly more likely to report limb edema , fatigue , fever , nausea and jaw osteonecrosis(1 % ) .Upfront zoledronic acid prevents bone loss in postmenopausal women with BC starting letrozole after tamoxifen .", "label": "", "metadata": {}, "score": "91.608116"}
{"text": "Western Ontario and McMaster Universities Osteoarthritis Index .YSJG : .Yi Shen Jian Gu granules .Declarations .Acknowledgements .This study was supported by Beijing Municipal Science and Technology Commission , China ( D131100002213001 ) .", "label": "", "metadata": {}, "score": "91.65157"}
{"text": "Duration : 5 years or less .Both direct [ 13 ] and indirect [ 14 ] comparisons showed greater mortality reduction with approximately 5 versus 2 years of tamoxifen .", "label": "", "metadata": {}, "score": "91.91597"}
{"text": "The most common cause of cancellation in the letrozole 5 mg / day group was an elevated serum FSH on cycle day 3 before the start of stimulation .", "label": "", "metadata": {}, "score": "92.014114"}
{"text": "View Article PubMed .Organization WH : WHO laboratory manual for the examination of human semen and sperm - cervical mucus interaction .1999 , Cambridge : Cambridge University Press , 4 .", "label": "", "metadata": {}, "score": "92.12213"}
{"text": "doi : 10 .1200/\u200bJCO .3744 PubMed CrossRef .N Engl J Med 356(18):1809 - 1822 .doi : 10 .1056/\u200bNEJMoa067312 PubMed CrossRef .", "label": "", "metadata": {}, "score": "92.41945"}
{"text": "10.1007/s10549 - 011 - 1351 - 3 PubMed View Article .Lancet Oncol 2012 , 13 : 275 - 284 .10.1016/S1470 - 2045(11)70389 - 8 PubMed View Article .", "label": "", "metadata": {}, "score": "92.648834"}
{"text": "Physician 's Choices .Received 10 September 2012 ; Accepted 20 November 2012 .Academic Editor : Mahmoud B. El - Tamer .Copyright \u00a9 2012 Asim Jamal Shaikh et al .", "label": "", "metadata": {}, "score": "93.80696"}
{"text": "Bisphosphonates are analogues to pyrophosphates that bind to hydroxyapatite crystals in bone and inhibit bone resorption .The third generation bisphosphonate inhibits osteoclastic resorptive activity partly through inhibition of farnesyl diphosphate synthase and protein prenylation [ 11 ] ; thereby they prevent skeletal complications .", "label": "", "metadata": {}, "score": "93.97003"}
{"text": "Tamoxifen an oral nonsteroidal , antiestrogenic compound with an intrinsic proestrogenic activity was first discovered in 1966 and first approved for clinical use in 1977 for metastatic breast cancer .", "label": "", "metadata": {}, "score": "94.03343"}
{"text": "The completion of this thesis would not have been possible without Dr. Michael Borenstein , Director of Biostast , Inc. , New Jersey , USA ; thanks to him .", "label": "", "metadata": {}, "score": "94.13966"}
{"text": "Authors ' Affiliations .Human Reproduction and Genetics Foundation .University Hospital , Dutch speaking Free University of Brussels .The Fertility Clinic , , Skive Regional Hospital , .", "label": "", "metadata": {}, "score": "94.16073"}
{"text": "Department of Pharmacy Practice , Kovai Medical Center and Hospital , Coimbatore 641014 , India .Received 9 September 2013 ; Revised 20 November 2013 ; Accepted 20 November 2013 ; Published 26 March 2014 .", "label": "", "metadata": {}, "score": "94.21545"}
{"text": "107 - 111 , 2012 .View at Google Scholar Abstract .Postmenopausal women with breast cancer ( BC ) are at increased risk for bone loss .", "label": "", "metadata": {}, "score": "94.63899"}
{"text": "Long - term follow - up has greatly strengthened these findings .The RRs were 0.53 in years 0 to 4 and 0.68 in years 5 to 9 , and there was no subsequent loss of the gains made during the first decade .", "label": "", "metadata": {}, "score": "95.11078"}
{"text": "We measured follicular diameter in 2 perpendicular planes and calculated the mean , while endometrial thickness was measured in the sagittal plane at the widest part of endometrial cavity .", "label": "", "metadata": {}, "score": "95.51962"}
{"text": "10.1093/annonc / mdl450 PubMed View Article .Ann Oncol 2008 , 19 : 877 - 882 .10.1093/annonc / mdm566 PubMed View Article .", "label": "", "metadata": {}, "score": "95.52896"}
{"text": "10.1007/s10549 - 010 - 1235-y PubMed Central PubMed View Article .Acta Oncol 2009 , 48 : 76 - 85 .10.1080/02841860802314738 PubMed View Article .", "label": "", "metadata": {}, "score": "96.098946"}
{"text": "Beijing Qihuang Medicine Clinical Research Center is responsible for quality control .Censors have regular visits ( once a month ) to monitor protocol violations , the recruitment rate , AEs and participant compliance .", "label": "", "metadata": {}, "score": "96.19583"}
{"text": "In the Z FAST group , at 12 months , BMD at lumbar spine ( LS ) was higher in the upfront group by 4.4 % ( .", "label": "", "metadata": {}, "score": "96.2288"}
{"text": "441 - 451 , 2013 .View at Google Scholar .21 , no . 8 , pp .1215 - 1223 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "96.611755"}
{"text": "The Functional Assessment of Cancer Therapy - Breast ( FACT - B ) , a quality of life instrument to assess the well - being of cancer patients , measures physical , social / family , emotional , and functional well - being as well as additional concerns commonly reported in breast cancer patients .", "label": "", "metadata": {}, "score": "96.98074"}
{"text": "Breast Cancer Res 2009 , 11 : R35 .10.1186/bcr2320 PubMed Central PubMed View Article .Cancer Res 2009 , 69 : 733s .", "label": "", "metadata": {}, "score": "97.01114"}
{"text": "Declarations .Competing interests .The authors declare that they have no competing interests .Authors ' contributions .EGP wrote the manuscript , NPP wrote the manuscript , PH wrote the manuscript , GP , revised the manuscript , EB revised the manuscript , HT revised the manuscript , BT revised the manuscript .", "label": "", "metadata": {}, "score": "97.94191"}
{"text": "The incidence of breast cancer rises with increasing age , about 80 % of breast cancer occur in women above 50 years of age and nearly half in the age group range of 50 to 69 [ 2 ] .", "label": "", "metadata": {}, "score": "98.0818"}
{"text": "Lancet Oncol 2012 , 13 : 420 - 432 .PubMed View Article .Copyright .\u00a9Peng et al . ; licensee BioMed Central Ltd. 2014 .", "label": "", "metadata": {}, "score": "98.457825"}
{"text": "Breast Cancer Res 2007 , 9 : R52 .10.1186/bcr1757 PubMed Central PubMed View Article .Eur J Cancer 2007 , 43 : 2523 - 2531 .", "label": "", "metadata": {}, "score": "98.61212"}
{"text": "PubMed .Nunn T : On Cancer of the Breast .London , UK : J. & A. Churchill ; 1882 .Love RR , Philips J : Oophorectomy for breast cancer : history revisited .", "label": "", "metadata": {}, "score": "98.909775"}
{"text": "Br J Cancer 2013 , 109 : 2951 - 2953 .10.1038/bjc.2013.707 PubMed Central PubMed View Article .Copyright .\u00a9 Schiavon and Smith ; licensee BioMed Central Ltd. 2014 .", "label": "", "metadata": {}, "score": "98.930374"}
{"text": "10.1016/S1470 - 2045(10)70257 - 6 PubMed View Article .Lancet Oncol 2011 , 12 : 1101 - 1108 .10.1016/S1470 - 2045(11)70270 - 4 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "99.360214"}
{"text": "Secondary outcome measures .Quality of life instruments .The Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) is a patient - reported outcome measure for assessing osteoarthritis of the knees or hips .", "label": "", "metadata": {}, "score": "99.54842"}
{"text": "The authors declare that there is no conflict of interests regarding the publication of this paper .Acknowledgments .It is with immense pleasure that the authors take this opportunity to express their deepest sense of everlasting gratitude to Dr. ( Mrs. ) Suchandra Sen , M.Pharm . and Ph.D. degrees Head of the Department , Department of Pharmacy Practice , KMCH College of Pharmacy , for her excellent guidance and their sincere thanks to Mr. A. Vijayakumar , M.Pharm . and Ph.D. degrees Asstistant Professor , Department of Pharmacy Practice , KMCH College of Pharmacy .", "label": "", "metadata": {}, "score": "99.90408"}
{"text": "Larger studies comparing CC , letrozole , and natural cycles in a single study are necessary to further characterize the effect of letrozole on hormonal dynamics and pregnancy rates .", "label": "", "metadata": {}, "score": "99.95328"}
{"text": "Breast cancer remains the leading cause of cancer related morbidity and mortality in women , worldwide .Every tenth new cancer diagnosed is that of breast , and nearly a quarter of cancers in the women are breast cancer .", "label": "", "metadata": {}, "score": "100.05255"}
{"text": "Acknowledgments .We would like to thank the Cridlan Fund for supporting GS .Competing interests .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "100.919174"}
{"text": "Insufficient kidney essence results in failure to nourish the related body constituents and organs , including bone and joints .Liver qi depression leads to stagnation of qi movement , manifested as pain [ 16 ] .", "label": "", "metadata": {}, "score": "102.836395"}
{"text": "Results .Patient characteristics were balanced , and there were no significant differences between the groups .The median age of patients was 45 years .", "label": "", "metadata": {}, "score": "103.14131"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .25 , no . 7 , pp .820 - 828 , 2007 .", "label": "", "metadata": {}, "score": "106.58434"}
{"text": "10.1097/gme.0b013e318148b28b PubMed Central PubMed View Article .Breast 2010 , 19 : 388 - 395 .10.1016/j.breast.2010.03.025 PubMed Central PubMed View Article .", "label": "", "metadata": {}, "score": "108.794495"}
{"text": "4 FACT - B : the Functional Assessment of Cancer Therapy breast cancer - specific quality of life tool ( Chinese version ) .5 BMD : bone mineral density .", "label": "", "metadata": {}, "score": "108.841736"}
{"text": "Bone Mineral Density .Delayed ZOL versus Immediate ZOL .In all the three studies ( Z FAST , ZO FAST , and E - ZO FAST ) , the lumbar spine ( LS ) bone mineral density ( BMD ) was measured .", "label": "", "metadata": {}, "score": "109.1886"}
{"text": "10.1016/j.fertnstert.2007.08.044 .View Article PubMed .Copyright .\u00a9 Bedaiwy et al ; licensee BioMed Central Ltd. 2011 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "111.17938"}
{"text": "In contrast to pre - menopausal women whose estrogen is produced in the ovaries , in post - menopausal women most estrogen is produced in the adrenal gland from the conversion of androgens .", "label": "", "metadata": {}, "score": "116.084366"}
{"text": "10.1016/j.fertnstert.2006.03.014 .View Article .Copyright .\u00a9 Papanikolaou et al ; licensee BioMed Central Ltd. 2011 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "117.66777"}
{"text": "Copyright \u00a9 2014 Pooleriveetil Padikkal Anagha and Suchandra Sen. This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "128.57736"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus", "label": "", "metadata": {}, "score": "131.6834"}
